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ABSTRACT 
 
Applications of Triazine Chemistry:  Education,  
Remediation, and Drug Delivery.  (May 2007) 
Susan E. Hatfield, B.S., University of Arkansas at Monticello 
Chair of Advisory Committee:  Dr. Eric E. Simanek 
 
 
 
Triazine chemistry has many applications from industrial usage, such as 
melamine resins, to academic interests in dendritic structures which may one day come 
to fruition as pharmaceutically applicable molecules.  Organic synthesis, using the 1,3,5-
triazine derivative 2,4,6-trichlorotriazine, cyanuric chloride, for practical applications 
was investigated.  By utilizing the selective reactivity of cyanuric chloride, a plethora of 
targets from small molecules to large dendrimers may be synthesized. 
Triazine chemistry was adapted to an educational application for the 
development of an undergraduate laboratory to synthesize simazine, a widely used 
herbicide.  The laboratory was designed to foster a sense of the applications of chemistry 
in the world and its effect on the environment and society. 
The modification of chitosan for herbicide remediation has been accomplished 
using triazine chemistry, as well.  Treatment of chitosan iteratively with cyanuric 
chloride followed by piperazine produces dendritic grafts from these flakes.  Dendrons 
of generation one through three were synthesized on chitosan backbones of low, 
iv 
medium, and high molecular weights.  The piperazine derivatives were shown to 
sequester more than 99% of atrazine from an aqueous 100 ppb solution in a 24 h period.   
Drug delivery applications of triazine-based dendrimers were investigated.  
Pegylated G3 dendrimers with molecular weights of 18 and 34 kDa with 9% and 17% 
iodine content by weight, respectively, were synthesized as potential macromolecular 
contrast agents.  The development of macromolecular contrast agents is of great interest 
to counteract the drawbacks associated with currently used, small molecule contrast 
media, including toxicity, extravasation into the extracellular space, and rapid clearance 
from the bloodstream.  Dendrimers are well suited for use as macromolecular media due 
to the unique properties of these molecules, including monodispersity and multivalency.   
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CHAPTER I 
INTRODUCTION:  TRIAZINE APPLICATIONS 
 
Triazines are six-membered aromatic heterocycles comprised of three carbon and 
three nitrogen atoms.  The three isomers shown below in Chart 1 are 1,2,3-triazine (1), 
1,2,4-triazine (2), and 1,3,5-triazine (3).  The 1,3,5-triazines are the oldest and most 
extensively studied of the isomeric forms.1,2  Given that 1,3,5-triazine is a symmetrical 
molecule, compounds of this type are often referred to as s-triazines.  The use of the 
term triazine in this work will solely refer to the 1,3,5-derivatives. 
 
Chart 1. Triazine isomers 
 
 
 1,3,5-triazine was unknowingly first synthesized by Nef in 1895 by treating 
hydrogen cyanide with ethanol in an ether solution saturated with hydrogen chloride.  
The resulting salt was then treated with base and distilled to give 1,3,5-triazine in low 
yields, 10%.  Nef incorrectly identified the product as a dimeric species.  However, in 
1954, Grundmann and Kreutzberger proved the compound to be a trimer of hydrogen 
cyanide, s-triazine.1,3 
 
This thesis follows the style of the Journal of the American Chemical Society. 
2 
 Triazine is thermally stable unless heated to above 600 °C where it decomposes 
to form hydrogen cyanide.  The triazine ring is fairly resistant to electrophilic 
substitution.  However, it may readily undergo ring cleavage with nucleophiles and is 
very sensitive to hydrolysis by water and other hydroxyl-compounds to a lesser 
degree.1,3  A variety of heterocycles can be prepared from 1,3,5-triazine by treatment 
with bifunctional amines or related compounds, and it may be used as an alternative for 
HCN in reactions.3  The most commonly used triazine derivatives are shown below in 
Chart 2, cyanuric acid (4), melamine (5), and cyanuric chloride (6). 
 
Chart 2. Common triazine derivatives 
 
 
Triazines were first synthesized as the compound known as cyanuric acid (4).  In 
1776, Scheele produced cyanuric acid through the pyrolysis of uric acid.  The common 
name of cyanuric acid was developed because, at that time, the compound was 
considered to be composed of cyanide groups, and it had been produced from uric acid.  
In 1820, Serullas repeated the work of Scheele to obtain cyanuric acid from cyanogens 
in water.  It was discovered in 1830 that the two products were indeed the same, and the 
structure was elucidated by Liebig and Wohler.1 
Cyanuric acid is only slightly water soluble and is thermally unstable.  At high 
temperatures, it decomposes to form toxic cyanic acid.1  Cyanuric acid exists 
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preferentially as the oxo tautomer (4b) rather than the hydroxy form (4a).4  (Figure 1)  
Commercial applications of cyanuric acid include stabilizers of swimming pool 
disinfectants, household bleach, industrials cleaners, dishwasher detergents, and general 
sanitizers.  Industrial preparation of cyanuric acid is accomplished through the pyrolysis 
of urea (5).4 (Scheme 1)  Cyanuric acid has been found to naturally occur in nature in 
soil humus.1 
 
 
Figure 1. Tautomerism of cyanuric acid 
 
Scheme 1. Industrial synthesis of cyanuric acid 
 
 
 Melamine (5) was prepared in 1834 by Liebig by fusing potassium thiocyanate 
with ammonium chloride.  The product was mostly melamine thiocyanate, but treating it 
with base provides the free melamine.1,3,5  It took over a century before commercial 
applications were fully realized.  Melamine is now produced in large quantities, mostly 
for the formation of resins.  In 1994, over 610,000 tons were produced worldwide.  
Currently industrial synthesis of melamine is from urea at 390–410 °C either non-
4 
catalytically under high pressure processes or catalytically using low-pressure processes.  
The net reaction is the same using any of these processes as shown in Scheme 2.5  
Naturally occurring melamine has been discovered in several meteorites which have 
reached earth.3 
 
Scheme 2. Industrial synthesis of melamine 
 
 
 Melamine is most often reacted with formaldehyde for the production of resins.  
This practice began in 1935 in Germany.6  The polymers formed from melamine-
formaldehyde resins have excellent chemical and physical properties.  The resins have 
numerous applications including laminates, glues and adhesives, molding compounds, 
coatings, and paper and textiles.6  The reaction of melamine with formaldehyde is shown 
below in Scheme 3.  Anywhere from one to six of the hydrogen atoms on the amine 
groups of melamine may be replaced by methylol groups.  Methylolmelamines are 
unstable due to the possibility of further condensation or resinification, as shown in 
Scheme 4 with a monomethylolmelamine, but similar reactions occur with the other di- 
or tri-methylolmelamines.5 
The oldest application of melamine resins is adhesives for wood such as plywood 
or particle board.6 Creating a foamed resin produces hard, yet flexible, lightweight 
materials which are used for sound insulation, fire protection, and cleaning products.7,8  
5 
Other applications include impregnating resins to treat papers for decorative purposes, 
paper auxiliaries to enhance wet tensile strength, leather tanning agents, strengtheners 
for building materials, concrete additives, ion-exchange resins, and wood preservatives.6  
 
Scheme 3. Initial reaction of formaldehyde and melamine 
 
 
Scheme 4. Condensation and resinification of methylolmelamine 
 
 
 Cyanuric chloride, trichlorotriazine, (6) was first synthesized in 1827 by Serullas, 
who converted cyanogen chloride to cyanuric chloride using sunlight.  However, the 
structure was not fully understood until 1867.  Thought to be the trimer of cyanogen 
chloride for many years, Liebig determined the correct structure by passing chlorine over 
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dry potassium thiocyanate.1  Today, cyanuric chloride is produced by the trimerization 
of chlorinated hydrocyanic acid.9 (Scheme 5) 
 
Scheme 5.  Industrial synthesis of cyanuric chloride 
 
 
 Cyanuric chloride has the most numerous applications of the triazine derivatives 
shown in Chart 2.  Arguably the most important attribute of cyanuric chloride is its 
ability to undergo nucleophilic aromatic substitution (SNAr).  It may be used as an 
analogous acid chloride equivalent in many organic transformations, including 
chlorination, dehydration, and coupling reactions.9-12  Table 1 summarizes some of the 
reactions in which trichlorotriazine may be used. 
 
Table 1. Reactions using cyanuric chloride as a reagent 
Reactant Product 
R−CO−OH R−CO−Cl 
R1R2−CH−OH R1R2−CH−Cl 
R−CH=N−OH R−C≡N 
HO−(CH2)n−COOH 
 
 
7 
 Cyanuric chloride can also be used as an oxidizing agent using Swern oxidation 
conditions utilizing DMSO.  The DMSO reacts with cyanuric chloride forming a 
complex which can be used to oxidize alcohols to give the carbonyl compound and 
dimethyl sulfide.10  The reaction of cyanuric chloride with DMF has been shown to 
produce a compound known as Gold’s salt (7).  The imminium salt prepared by Gold in 
1960 is a Vilsmeier-Haak type reagent.  The reagent transforms amines to N,N-
dimethylamidines, ketones to N,N-dimethylenamino ketones, and amides to N’-acyl-
N,N-dimethylformamidines as shown below in Scheme 6.9,10,13,14 
 
Scheme 6. Reactions of Gold’s salt 
 
 
 Another important use of trichlorotriazine is for coupling reactions such as 
peptide coupling.  The compound may be used as itself or as the 2-chloro-4,6-
dimethoxy-1,3,5-triazine derivative (CDMT), with or without the addition of N-
methylmorpholine.  The reagents may be in solution or attached to a solid-support.  The 
reactions proceed with high diastereoselectivity and enantioselectivity to obtain high 
8 
yields without racemization.  Scheme 7 provides the asymmetric synthesis of 
Lometrexol, a potential anticancer agent, using CDMT and NMM.10,12 
 
Scheme 7. Asymmetric synthesis of Lometrexol 
 
  
Cyanuric chloride has temperature-dependent differential reactivity for 
displacement of chlorides with nucleophiles during SNAr.  Scheme 8 illustrates this 
process for the incorporation of amino nucleophiles.  As a general rule, which varies 
with the reactivity of the nucleophile chosen, the first substitution occurs at low 
temperatures, 0 °C, the second substitution at approximately room temperature, and the 
third at elevated temperatures, 70–100 °C.15-19  This property allows substitution of three 
different nucleophiles onto the same triazine core which provides a vast array of possible 
triazine derivatives and applications. 
 
Scheme 8. Differential reactivity of cyanuric chloride 
 
 
 The first triazine herbicides were developed in 1952.  A  Swiss group led by J. R. 
Geigy produced two compounds with remarkable herbicidal activity, simazine (8) and 
9 
chlorazine (9).20  Alkylaminotriazines are among the most widely used herbicides today.  
The most predominantly used derivative being atrazine (10).9,12   
 
Chart 3. Triazine herbicides 
 
 
 Reactive dyes are synthesized from cyanuric chloride through substitution with 
one or more alkoxy- or amino-containing chromophores.  Reactive dyes, in general, 
contain functional groups that can undergo addition or substitution reactions with the 
amino or hydroxy groups present in the fiber.  Rattee and Stephen were able to use basic 
aqueous conditions to fix triazine dyes onto cellulose.  This was a breakthrough that led 
to commercial development.  Procion-MX dyes were introduced in 1956 by ICI followed 
by Cibacron dyes from Ciba-Geigy in 1957.   
There are two main categories of reactive triazine dyes, mono- or double-anchor 
dyes.  Dyes such as Procion MX, Procion H, Procion P, or Cibacron are mono-anchor 
dyes, and Procion HE is an example of a double-anchor dye. (Chart 4)  The 
dichlorotriazine dyes are more reactive and may be applied without any heat.  However, 
these dyes are also more sensitive to hydrolysis, and an appropriate buffer is usually 
added to increase the stability.  Due to reduced activity of the monochlorotriazine 
derivatives, these compounds require heat for fixation and are well suited for printing 
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processes.  The double-anchor compounds contain two monochlorotriazine units linked 
by a bridging group such as a diamine.  The synthetic strategy utilized to produce these 
compounds allows the incorporation of two different chromophores into a single system.  
This greatly expands the range of attainable colors.12,21 
 
Chart 4. Mono-anchor and double-anchor triazine reactive dyes 
 
 
Trichlorotriazine is also the basis for optical brighteners or fluorescent whitening 
agents.  These compounds are employed to absorb ultraviolet light and emit blue 
fluorescent light.  They are often used to mask the undesirable yellow tint in white 
substrates such as fabric or paper.  These compounds are also used in detergent 
formulations to make laundered fabrics whiter or colors brighter.  The most common 
derivatives contain 4,4’-diaminostilbene-2,2’-disulfonic acid (11) and have been used 
since 1941.  A wide variety of amino, hydroxy, sulfo, or alkoxy groups may be 
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incorporated into the compound, and the triazine may have a chlorine retained in the 
structure or the chlorine may be substituted by amines.1,12 
 
 
 
 Due to the ability to substitute a wide variety of nucleophiles onto 
trichlorotriazine, as well as the capability to vary the groups attached during each 
substitution, interest in triazine dendrimers has grown.22  Dendritic structures have been 
investigated for years.  The perfectly branching structures are reminiscent of a motif 
found in nature including, among others, snowflakes, trees, and neurons.23  Dendrimers 
are highly branched, globular, multivalent, monodisperse molecules with synthetic 
versatility and many possible applications ranging from catalysis to electronics and drug 
delivery.22,24-26   
The concept of dendrimers was introduced in 1978 by Vögtle who synthesized 
branched amines through repetitive reactions.27  In 1985, two groups, Tomalia and 
Newkome, independently reported the divergent synthesis of dendritic systems in which 
the synthesis begins at the core and reactions are carried out on the periphery until the 
desired dendrimer is reached.28,29  In 1990, the concept of convergent synthesis of 
dendrimers was introduced by Fréchet and co-workers.  Using the convergent route, the 
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synthesis begins with the periphery groups, and a dendron of the desired size is coupled 
to a core in the final step.30,31  Both synthetic strategies are illustrated in Figure 2. 
 
 
Figure 2. Divergent and convergent dendrimer synthetic strategies 
 
 The synthesis of triazine-based dendritic structures from cyanuric chloride for 
use as Gd chelating ligands in magnetic resonance imaging (MRI) applications were 
reported in 1996.32  Accounts of dendrimers synthesized from trichlorotriazine by 
nucleophilic aromatic substitution were first published in 2000 by the Simanek group at 
Texas A&M University.  The melamine based dendrimer (12) was synthesized using 
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both the convergent and divergent route.33,34  Other groups have since reported triazine 
dendrimers and this subject has been reviewed by Steffensen and co-workers.22,35 
 The work in the Simanek group has focused on improving melamine dendrimer 
synthetic strategies.  This has been accomplished by exploiting the differential reactivity 
of cyanuric chloride to incorporate diverse reactive groups for further manipulations and 
by utilizing orthogonal protecting groups or diamines with chemoselective reactivity.36-38  
Improvements in synthetic strategies are necessary for applications of these dendrimers 
to be widespread.  
 
 
 
Applications pursued in the Simanek group have included endeavors to educate 
students on dendrimer chemistry itself, as well as triazine chemistry and its 
applications.39,40  Another field of interest has been environmental remediation by 
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attachment of triazine dendrons to solid supports.41-44  Biologically relevant applications, 
such as drug delivery, have been a major focus with investigations of disulfide exchange 
for covalent conjugation of drugs,45-47 encapsulation of drugs,48,49 and the  in vitro and in 
vivo studies of melamine dendrimer toxicity and biodistribution.50-52  The limits of 
triazine dendrimer chemistry have not yet been reached as new synthetic strategies have 
been pursued53 and the possibility of large scale syntheses is being explored for these 
multivalent molecules which may be readily tailored to the application of interest. 
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CHAPTER II 
SYNTHESIS OF A TRIAZINE HERBICIDE AS AN 
UNDERGRADUATE LABORATORY EXERCISE 
 
Introduction 
 For most students who take undergraduate chemistry courses, it is often difficult 
to make a connection between concepts learned and real life.  Many don’t realize the 
numerous practical applications of chemistry that surround them.  When a correlation is 
made between the world around us and the material learned, it can serve to bring about a 
whole new level of understanding.   
Nucleophilic aromatic substitutions are less commonly performed in 
undergraduate laboratories than electrophilic aromatic substitution reactions.  In 
addition, the products of these reactions often do not seem to have relevance to life 
outside of the laboratory for the students.  Triazine herbicides are synthesized using 
nucleophilic aromatic substitution and have very important agricultural, economical, and 
environmental impacts in the world today. 
 The most commonly studied nucleophilic aromatic substitution reactions involve 
2,4-dinitrobromobenzene or 2,4-dinitrochlorobenzene as shown in Scheme 9.  The 
electron withdrawing groups activate this reaction because the intermediate is stabilized 
by resonance, and the charge can be delocalized.  
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Scheme 9. Nucleophilic aromatic substitution 
 
 
 The synthesis of atrazine, as shown in Scheme 10, is very similar.  It also 
involves nucleophilic aromatic substitution and resonance stabilization.  Atrazine is 
synthesized from cyanuric chloride by the sequential reaction with isopropylamine and 
ethylamine.    Other herbicides based on 1,3,5-triazine are summarized in Table 2. 
 
Scheme 10. Synthesis of Atrazine 
 
    
The triazine herbicide atrazine has been one of the most widely used herbicides 
in the production of corn, sorghum, and other crops for forty years in the U.S.  It is a pre-
emergent herbicide used to control broadleaf and grassy weeds.  Its mode of action is 
through selective disruption of photosynthesis to kill weeds, resulting in increased crop 
production.54   
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Table 2.  Common 1,3,5-triazine herbicides 
 
Herbicide R1 R2 R3 
Atrazine Cl NH
 
HN  
Cyanazine Cl NH 
HN
N
 
Simazine Cl NH HN  
Terbuthylazine Cl NH HN
 
Trietazine Cl NH N
 
Prometon O-CH3 NH
 
HN
 
Terbumeton O-CH3 NH HN
 
Ametryn S-CH3 NH
 
HN  
Desmetryn S-CH3 NH HN
 
Prometryn S-CH3 NH
 
HN
 
Simetryn S-CH3 NH HN  
Methoprotryne S-CH3 O NH HN
 
 
 
Due to the Safe Drinking Water Act of 1974, the EPA is required to determine 
the concentration of chemicals which may cause health problems.  Atrazine is 
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moderately water-soluble and can be present in runoff from crop fields.55  Atrazine is 
commonly detected in ground and drinking water and has been linked to cancer and 
endocrine gland disruption in people.  For atrazine, the maximum contaminant level 
(MCL) is set at 3 parts per billion, ppb or μg/L.  Short-term exposure at levels above the 
MCL may cause heart, lung, or kidney congestion along with low blood pressure, 
muscle spasms, adrenal gland damage, or weight loss.  The long-term effects range from 
weight loss and cardiovascular damage to muscle degeneration or cancer.35   
The EPA has considered restricting or banning its use, but long-term costs would 
range from $295-$665 million a year.54  Estimates have shown that nonuse of herbicides 
would increase production costs for the grower by $21 billion annually and crop yields 
would be reduced by 5-67%.56  The money lost from yield reductions or more expensive 
herbicide replacements would be passed down to livestock producers and eventually to 
consumers.  Financial and agricultural disadvantages must be weighed against 
environmental concerns. 
 Although average concentrations in streams and wells rarely exceed the safe 
water standards, water monitoring has shown that atrazine is found in two-thirds of all 
samples from agricultural streams.  In shallow ground water where runoff must travel 
further, providing more chances for absorption or degradation, the most common 
compounds found included atrazine and one of its degradation products deethylatrazine 
(DEA).57  Atrazine and its metabolites are often found at levels exceeding the MCL in 
runoff in the days following application, up to 100 days for atrazine and up to 50 days 
for DEA and deisopropylatrazine (DIA).58 
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 Triazine herbicides are also used on residential lawns and golf courses.  Although 
atrazine usage is regulated by the EPA for agricultural application, regulations can not 
be easily enforced for residential application.  In this case recommendations are given 
for maximum application, especially regarding exposure of children to treated lawns.10  
In urban streams and shallow ground water, atrazine, DEA, and simazine are among the 
most frequently detected herbicides.57  There are no extensive studies on the effects on 
DEA and DIA, although these metabolites are commonly found in the same locations as 
atrazine.  There are no set MCL values for DEA and DIA, and the lack of consideration 
to these metabolites’ impact on the environment underestimates atrazine’s total impact.58  
Despite all of this data, the EPA has recently issued a reregistration eligibility decision 
for atrazine.  The 2006 statement concluded that although the herbicides have a 
neuroendocrine toxicity mechanism which could result in developmental and 
reproductive complications, the cumulative effects present no reasonable harm to any 
general population of the U.S. 59   
 Herbicides are classified according to selectivity, time of application, 
translocation in the plant, or mechanism of action.  For mechanism of action, there are 
seven major classes of herbicides:  growth regulators, seedling growth inhibitors, 
photosynthetic inhibitors, amino acid synthesis inhibitors, lipid synthesis inhibitors, cell 
membrane disruptors, and pigment inhibitors.  Atrazine is a photosynthetic inhibiting 
herbicide.60   
 Photosynthesis is the net reaction in plants which converts carbon dioxide and 
water to carbohydrates, oxygen, and water using energy from sunlight.  Photosynthesis is 
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a two-part process:  the light-dependent reactions in which chlorophyll and other 
pigments absorb light energy for the formation of ATP, NADPH, and O2, and the 
carbon-assimilation or carbon-fixation reactions, sometimes referred to as the dark 
reactions, in which the ATP and NADPH are used to reduce CO2 to form 
carbohydrates.61   
Photosynthesis occurs in the chloroplasts of leaves.  Inside this organelle is a 
fluid, stroma, and vesicles called thylakoids which are arranged into stacks known as 
grana.  It is in the thylakoid membranes that the light reaction centers are located.  The 
primary light absorbing molecules, chlorophyll a and b, are associated with specific 
binding proteins forming light-harvesting complexes (LHC’s).  In the LHC, chlorophyll 
molecules are fixed in relation to the thylakoid membrane, to other necessary protein 
complexes, and to each other.  Other light absorbing pigments such as β-carotene and 
lutein are referred to as accessory pigments.  These pigments absorb light at wavelengths 
not absorbed by the chlorophylls.61 
Light-absorbing pigments are arranged into photosystems.  Some of these 
pigments are considered light-harvesting or antenna molecules because they are not 
directly associated with the reaction center.  Instead, these pigments absorb light energy 
and transfer it to the reaction center.  When antenna chlorophyll, for example, absorb 
energy, the excited molecule then transfers the energy to a neighboring chlorophyll 
exciting this new molecule as the original one returns to its ground state.  This continues 
until the photochemical reaction center is reached.  When the excited chlorophyll 
molecule in the reaction center transfers an electron to a nearby electron acceptor, an 
21 
electron from a nearby electron donor is transferred to the reaction center chlorophyll.  
At this point, the electron acceptor in the chain is negatively charged and the electron 
donor in the chain is positively charged, and the charge separation initiates the 
oxidation-reduction reactions of photosynthesis.61  The thylakoid membranes contain 
four membrane proteins:  photosystem II (PSII), cytochrome b6f, photosystem I (PSI), 
and the ATP synthase complex.62,63 (Figure 3)  
 
 
Figure 3.  Thylakoid membrane-bound proteins for photosynthetic electron transport*  
 
As shown in the Z-scheme in Figure 4, excitation of the PSII reaction center 
P680 transfers an electron to pheophytin which passes the electron to a protein-bound 
plastoquinone, QA, which passes it to another plastoquinone, QB, which is more loosely 
bound.  QA and QB are bound into the D2 and D1 proteins, respectively.  QB accepts two 
                                                 
* Reproduced with permission from “Electron Transfer between Membrane Complexes and Soluble 
Proteins in Photosynthesis” Hervás, M.; Navarro, J. A.; De La Rosa, M. A., Acc. Chem. Res.2003, 13, 799.  
Copyright 2007 American Chemical Society. 
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electrons from QA and two protons from water to form fully reduced plastohydroquinone 
(PQH2).  The binding affinity of PQH2 to this site is low.  Another plastoquinone 
molecule may displace PQH2 to bind to the D1 protein and is then referred to as QB.  
PQH2 passes the electrons on to the cytochrome b6f complex, from which they will 
continue on to PSI.62,64  Figure 5 shows PSII and the binding site for QB on the D1 
protein that triazine herbicides may bind to block the electron flow, preventing ATP 
production.  The triazine serves as a non-reducible analog to plastoquinone.61,65,66 
Figure 4.  Z-scheme showing flow of electrons through photosystems† 
 
                                                 
† Reproduced with permission from “A Role for Manganese in Oxygen Evolution in Photosynthesis” 
Sauer, K., Acc. Chem. Res. 1980, 13, 250. Copyright 2007 American Chemical Society. 
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Figure 5.  PSII complex showing electron transport and site of action of triazine herbicides‡ 
 
The PSII binding site was identified using photoaffinity labeling studies by 
Arntzen and co-workers in 1981.  Azido-atrazine was used to covalently bind to the site 
in the receptor protein.  UV irradiation of thylakoids in the presence of 
azido[14C]atrazine produces a reactive nitrene that covalently links the azido-atrazine to 
the chloroplast membranes.  The membrane polypeptides may then analyzed by sodium 
dodecyl sulfate/polyacrylamide gel electrophoresis, SDS-PAGE.  Subsequent 
fluorography locates the 14C label and identifies the association of the azido-atrazine 
with the 34- to 32-kDa polypeptide size class.  Binding did not occur in triazine-resistant 
chloroplasts.67  This polypeptide is now known to be the D1 protein.66  The crystal 
structure of the PSII system with atrazine bound has been resolved.  The structure shows 
H-bonding and hydrophobic interactions to be the major contributors to the binding of 
atrazine in the QB site.68 
When plants are treated with atrazine, the QB binding site is blocked and the flow 
of electrons through PSII are therefore blocked.  This causes an accumulation of singlet 
                                                 
‡ Reproduced with permission from “Light-dependent herbicides:  an overview” Hess, F. D., Weed Sci. 
2000, 48, 161. Copyright 2007 BioOne. 
24 
chlorophyll since the excited molecules cannot transfer an electron to PSII.  Some 
singlet chlorophyll is converted to triplet chlorophyll through intersystem crossing 
(i.s.c.).  Triplet chlorophyll may then directly initiate lipid peroxidation or may react 
with oxygen to form singlet oxygen which would initiate lipid radicals in the 
polyunsaturated fatty acids eventually causing membrane damage and leading to plant 
death.  Schemes 11 and 12 below show the possible pathways of singlet chlorophyll 
upon activation and the lipid peroxidation process.66  Triplet chlorophyll and singlet 
oxygen are normally produced during photosynthesis but are typically produced in small 
quantities and are adequately quenched by carotenoids in the membrane.65,66 
 
 
Scheme 11.  Excitation of chlorophyll to 1CHL and the possible pathways including electron transfer to 
PSII, quenching of 3CHL or 1O2 by carotenoids, and initiation of lipid radicals§ 
 
 
Scheme 12.  Lipid Peroxidation of plant membrane polyunsaturated fatty acids§ 
 
 
                                                 
§ Reproduced with permission from “Light-dependent herbicides:  an overview” Hess, F. D., Weed Sci. 
2000, 48, 161, 168 . Copyright 2007 BioOne.  
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Resistance to triazine herbicides has been shown to be caused by a single point 
mutation which codes for substitution of a glycine residue in place of a serine residue in 
the binding pocket.68-70  However, atrazine is metabolized and detoxified in corn and 
other resistant species by three primary routes:  2-hydroxylation, N-dealkylation, and 
glutathione conjugation.71-73  Scheme 13 provides the metabolic pathways of atrazine in 
sorghum.71 
 
 
Scheme 13.  Metabolic pathway of atrazine in sorghum.  Major pathways are shown with red arrows, blue 
arrows indicate minor pathways, and the green arrows indicate a hypothesized reaction.  The structure in 
brackets was not isolated. 
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The enzymatic breakdown of atrazine by microorganisms had been extensively 
studied.  Scheme 14 was determined by Professor Larry Wackett at the University of 
Minnesota.74  Atrazine can be degraded to DEA, DIA, dealkylatrazine (DAA), and 
hydroxyatrazine.  Both bacteria and fungi found in soil have been shown to degrade 
atrazine to various metabolites.75 
 
Scheme 14.  Atrazine degradation pathway map 
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Experimental 
Materials and Methods. ACS-grade solvents were used for all the synthetic 
preparations. Distilled water was obtained in-house.   All reagents and solvents were 
purchased from Acros Organics or Aldrich Chemical Co. and were used without further 
purification.  1H NMR and proton decoupled 13C NMR spectra were acquired on a 
Varian 300 MHz spectrometer using CDCl3 or DMSO-d6.  NMR chemical shifts are 
listed relative to tetramethylsilane in parts per million (ppm) and were referenced to the 
residual proton or carbon peak of the solvent.   
Synthesis of Atrazine.  Add cyanuric chloride (350 mg, 1.90 mmol) to 1 mL of 
acetone in a round bottom flask while stirring to obtain a slurry solution.  Add isopropyl 
amine (0.17 mL, 1.86 mmol), place the flask in an ice bath, and allow it to cool while 
stirring for approximately five minutes.  Then, a white precipitate is formed by adding 
5.6 M NaOH (0.39 mL, 2.17 mmol).  The reaction mixture is stirred while in the ice bath 
for 20-30 minutes, checking the progress of the reaction by TLC.  When the substitution 
is complete as determined by TLC, the flask is placed in a water bath and heated at 35-
40 °C.  Upon heating, ethylamine, 70% in water, (0.16 mL, 1.96 mmol) is added.  A very 
thick white precipitate is formed by adding 5.6 M NaOH (0.28 mL, 1.57 mmol), and the 
reaction mixture is allowed to stir for 20-30 minutes while checking the progress by 
TLC.  When the reaction is complete, distilled water (2.50 mL) is added to precipitate 
the product, and the flask is allowed to cool to room temperature.  The product is then 
filtered, rinsing well with distilled water, dried, and weighed.  Product acquired is a 
white powder.  Yield:  356-373 mg (87-91%).  Melting point 165-168 °C.  1H NMR 
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(300 MHz, CDCl3) δ:  6.33 (s, NH), 6.02 (s, NH), 5.40 (d, J=7.15, NH), 5.25 (s, NH), 
5.12 (d, J=8.25, NH), 4.15 (m, 1H), 3.40 (m, 2H), 1.20 (m, 9H)  13C NMR (75.5 MHz, 
CDCl3) δ:  168.06, 165.57, 164.80, 42.86, 35.79, 22.88, 22.38, 14.64. 
Synthesis of Simazine.  A 0.5 M cyanuric chloride stock solution (5 mL, 2.5 
mmol) is placed in a round bottom flask and into an ice bath to cool for about 10 min. 
while stirring.  To this solution, a 1.0 M ethylamine solution in aqueous acetone (10 mL, 
10.0 mmol) is added.  After 5 min., the ice bath is removed and the reaction is allowed to 
stir for 15 min. as it comes to room temperature.  The addition of distilled water (30 mL) 
precipitates the simazine which can be collected by filtration, rinsed well with distilled 
water (2 x 30 mL), dried, and weighed.  Product obtained is a white solid.  Yield:  449 
mg (89%).  Melting point:  225-227 oC.  TLC:  Rf =0.25 using 3:1 hexanes:ethyl acetate.  
Procedure modification:  Allow reaction to stir for 30 min. at room temperature, and 
also, when filtering, final rinse should be with methanol (1 x 30 mL).  1H NMR (300 
MHz, DMSO-d6) δ:  7.78 (t, J= 4.52 Hz, NH), 7.73 (t, J=5.13 Hz, NH), 7.67 (t, J=5.01 
Hz, NH), 7.49 (m, NH), 3.24 (dd, J=5.98 Hz, 2H), 3.24 (dd, J=6.96 Hz, 2H), 1.05 (m, 
6H)  13C NMR (75.5 MHz, DMSO-d6) δ:  168.12, 167.48, 165.36, 165.13, 164.74, 35.00, 
34.96, 34.86,  14.83, 14.65, 14.37, 14.28. 
Results and Discussion 
The first method investigated for developing the undergraduate laboratory was 
adopted from U.S. patent 4,166,909 using sodium hydroxide as the base.76  (Scheme 15)  
Due to time constraints in the allotted laboratory time period, this method proved to be 
too lengthy to be completed in a normal 3 hour lab session.  Modifications of the 
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procedure were made to simplify the synthesis.  The synthetic target was altered to 
afford the triazine herbicide simazine rather than atrazine.  Being symmetrical, simazine 
requires no monitoring of reaction progression in the middle of the procedure.  Using 
this method, four equivalents of ethylamine may be added to serve as the reactant and to 
preclude the use of an exogenous base. (Scheme 16) 
Scheme 15.  Synthesis of atrazine using sodium hydroxide as an exogenous base. 
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Scheme 16.  Synthesis of simazine by the reaction of cyanuric chloride with ethylamine. 
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  During the first semester the laboratory was implemented, the preparation of 
simazine went fairly well when performed by students.  Approximately 85% reported 
characterization data consistent with simazine as the major product (mp ~225-227 oC , Rf 
~0.25).  Approximately 54% of the students observed two compounds present by TLC, 
the second with Rf ~0.55.  In most cases, the second spot was barely visible.  
  The second product is in most cases the dichlorotriazine that results from a single 
substitution on the triazine ring.  The two possible causes for its appearance are 
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inadequate reaction times, or an error in measurements resulting in stoichiometric 
differences.  Our solution to this problem, which has been adopted in subsequent 
semesters, is to run the reaction for 30 minutes at room temperature instead of 15 
minutes.  Students using a 30 minute reaction time achieved a higher success rate in that 
fewer reported two spots visible by TLC. 
  The product obtained is difficult to dry in the allotted time.  When the melting 
points and yields must be calculated within the three hour period, a methanol rinse of the 
product removes residual water, as well as most of the unwanted dichlorotriazine.  
Recrystallization of the product from methanol is recommended for optimal purity but 
has not been implemented into the lab procedure at Texas A&M University.  When the 
students are careful, utilize the full 30 min. reaction time at room temperature, and rinse 
well with methanol, little to no dichlorotriazine is detected in the final product. 
  Comments from students concerning the laboratory exercise were 
overwhelmingly positive when considering the ease of synthesis, clarity of procedural 
steps, interest level, and practicality.  Negative comments from students were of the 
amount of time necessary to perform the experiment.  However, the students were able 
to complete the lab in the allotted 3 hour time period with no difficulty when kept on 
task. 
The background material available to the students on the mode of action and 
degradation of atrazine allows incorporation of biochemistry and simple biology to the 
curriculum.  This works particularly well for the intended course of this exercise, an 
introductory biochemistry and organic chemistry course for non-science majors.  Since 
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the development of this laboratory experiment, it has been adopted into the Texas A&M 
University chemistry curriculum.  Also, the experiment sparked interest in the 
development of an entire course based on the chemistry and biology involved with Texas 
agriculture.  The students synthesize simazine and propose studies to test the 
effectiveness of a simazine formulation.  They then plant seeds according to their 
proposed methods and make observations on the effectiveness of their plan versus the 
effectiveness of the herbicide.  Other studies in the course involve computer modeling to 
design novel triazine herbicides, synthesis of novel herbicides, and another round of 
testing on plants.  The final study is ELISA assays of water samples from various sites in 
Texas, models of the ELISA strips to demonstrate their knowledge of the topic, and 
discussions about the results of the test as in applies to environmental impacts and 
regional importance of atrazine. 
Conclusions 
This experiment achieves several goals.  It allows the students to perform a 
simple synthesis involving nucleophilic aromatic substitution and obtain a product in 
relatively high yield and purity.  The product obtained is also very interesting and 
important to society today.  This experiment may allow students to debate over whether 
economics and food production are more important than environmental concerns, or vice 
versa.  A wide variety of discussions ranging from photosynthesis to farming techniques 
enhances a multi-disciplinary lesson which broadens the students’ knowledge base.  
Most importantly, it allows students to see an example of how chemistry is relevant to 
and impacts the world. 
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CHAPTER III 
MODIFICATION OF CHITOSAN FOR ATRAZINE SEQUESTRATION 
 
Introduction 
 Chitosan is the deacetylated derivative of chitin, the second most abundant 
naturally occurring polysaccharide after cellulose.  Chitosan is inexpensive, readily 
available, biodegradable, non-toxic, and may be easily functionalized at the amine group 
in the C-2 position.  Chitosan and its derivatives have found applications in many 
different fields including antimicrobial agents, textile chemicals, biomedical 
applications, chromatographic separations, food and nutrition, cosmetics, and 
wastewater treatment.77-82  Table 3 gives examples of the use of chitosan or its 
derivatives as adsorbents of undesirable pollutants. 
The primary amines of chitosan offer a convenient handle for grafting functional 
polymers. To this end, several groups have investigated dendrimer-chitosan hybrid 
materials.    Roy, Sashiwa, and Aiba et al. have reported the attachment of various 
PAMAM dendrimers and dendrons to chitosan.  They also reported the attachment of 
polypropyleneimine dendrimers and dendrons of gallic acid and tri(ethylene glycol) to a 
chitosan backbone.  These materials showed no activity per se, but were well 
characterized by NMR and GPC.83-90  Tsubokawa et al. report the divergent synthesis of 
PAMAM dendrons on chitosan powder.  Again, while no activity data was provided, the 
materials were characterized by IR and SEM.91  The modification of chitosan as a solid 
support to perform atrazine sequestration from aqueous solutions is accomplished by the 
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incorporation of constrained secondary amines.   Multiple amine groups may be easily 
incorporated by the divergent growth of highly branched dendritic molecules based on 
melamine. 
 
Table 3.  Chitosan adducts as adsorbents of pollutants. 
Guest Author B/C* Chitosan formulation Material Removed 
Blackburn92 B Flakes Reactive Red, Direct Black, 
and Acid Blue 
Chiou93 B Crosslinked beads Reactive Red 
Chiou94 B Crosslinked beads Reactive, Direct, and Acid 
Dyes 
 
 
Dyes 
Juang95 B Ground flakes Reactive Red, Yellow, and 
Blue 
Lasko96 B,C Flakes Ag+, Ag(NH3)2+, Ag(SCN)32-, 
and Ag(S2O3)23- 
Boddu97 B,C Coated onto ceramic alumina Cr(VI) 
Peniche-Covas98 B,C Mercaptan derivative Hg2+ 
Prasher99 B Flakes Zn, Cu, Cd, and Pb 
Pedrosa100 B Microspheres with PVA and  
sulphonated Cu(II)- 
phthalocyanine 
Fe, Zn, Cu, and Mn 
Lasko101 B N- and S- derivatives  Cu2+, Cd2+, Pb2+, and Fe2+ 
Yen102 B Coated onto sand Cu2+ 
Wan Ngah103 B Beads and crosslinked beads Cu(II) 
Wang104 B Crosslinked with crown ethers Pb2+, Cu2+, Cr3+, and Ni2+ 
Kartal105 B Flakes and powder Cu, Cr, and As 
Prasher106 B Flakes Cu2+, Pb2+, Cd2+, and Zn2+ 
Cervera107 B Ground flakes Cd and Cr 
 
 
 
 
 
 
 
Metals 
Modrzejewska108 C Membranes (modified) Cr(VI) 
Fávere109 B,C Microspheres H3O+ and Fe(III) 
Yoshizuka110 B Crosslinked particles  Methyl parathion (pesticide) 
with/w/o Ag+ 
 
 
Other 
Krysteva111 B,C Flakes Organic acids and 
polyphenols from wine 
production (vinasse) 
*The assay of interest employs either a (B)atch or (C)olumn method 
 
Atrazine is one of the most widely used herbicides for the production of corn, 
sorghum, and cotton in the U.S.112  Due to its wide usage, atrazine is commonly detected 
in ground and drinking water, often at levels exceeding the EPA drinking water limit of 
3 ppb.113  Atrazine has also been linked to health risks in humans and animals.  
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However, economic concerns and lack of a suitable alternative have allowed for its 
continued use.114  For this reason, methods to remove atrazine from drinking water or 
prevent atrazine from entering ground water are very important.  The EPA approved 
method of removal for atrazine from drinking water is granular activated charcoal.41  
However, this non-selective adsorbent is expensive, and its activity is dependent on the 
type of carbon used and the characteristics of the wastewater.92   
The Simanek group has demonstrated that atrazine readily undergoes 
nucleophilic aromatic substitution particularly well with constrained secondary amines.  
The amines, when placed on a solid support, provide a method for covalent atrazine 
sequestration (Equation 1).41  A wide range of solid supports have been investigated 
including commercially available polystyrene beads intended for peptide synthesis,41 
polystyrene subsequently modified with isonipecotic acid,44 silica gels,115 
thermomorphic polyacrylamides (a transiently solid support),116 and organoclays.117  
 
Equation 1 
 
  
Experimental 
Materials and Methods.  Cyanuric chloride 99% was purchased from Acros 
Organics.  Piperazine, N,N-diisopropylehtylamine (DIPEA), ninhydrin, and chitosan 
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with molecular weights of approximately 50,000 g mol-1 (low), 200,000 g mol-1 
(medium), and 1,000,000 g mol-1 (high) were purchased from Aldrich.  The atrazine 
concentrations were measured by atmospheric pressure chemical ionization (APCI) 
using a Thermofinnigan LC Q Deca mass spectrometer.  Quantitation was performed by 
comparing the relative area of the unknown peaks to a standard curve over a linear 
region of 5-125 ppb concentration of atrazine.  Characterization of the chitosan materials 
was achieved using IR spectroscopy on a PerkinElmer Spectrum One FTIR spectrometer 
equipped with an Attenuated Total Reflectance sampling accessory.  XPS measurements 
were taken with a Kratos Axis Ultra Imaging X-ray photoelectron spectrometer using a 
powder holder.  TGA measurements were taken with a Netzsch TG 209 °C TGA.  The 
materials were heated under nitrogen from 25 to 850 °C at a ramp of 10 °C per minute. 
Synthesis and Characterization.  Samples of chitosan flakes (2.0 g) of low, 
medium, and high molecular weights are washed with 1 M sodium hydroxide solution 
and rinsed with three 100-mL portions of water, or until the filtrate is no longer basic.  A 
cold solution (100 mL) of five equivalents (0.5 M) of cyanuric chloride and five 
equivalents of Hünig's Base in tetrahydrofuran is added to the chitosan, and the reaction 
mixture is shaken at 0 °C overnight.  The chitosan is then rinsed with three 100-mL 
portions of methanol and one 100-mL portion of tetrahydrofuran.  The sample is treated 
with a solution of ten equivalents of piperazine (100 mL of 1.0 M) and ten equivalents of 
Hünig's Base in a 9:1 solution of tetrahydrofuran:methanol, and shaken overnight at 
room temperature.  The samples are then washed with three 100-mL portions each of 
methanol and water followed by one 100-mL portion of ethyl acetate.  Iterative reactions 
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of the material in this manner result in dendron growth on the chitosan surface.  Upon 
completion of each synthetic transformation, 300-mg samples are taken.  The samples 
are analyzed using ATR-FTIR.  A ninhydrin test is performed by placing a few flakes of 
each sample into individual vials, adding ninhydrin solution, heating, and observing any 
color change. 
Acid hydrolysis of the derivatized chitosan materials was accomplished by 
placing 20 mg of the material in 1 mL of 0.1 M HCl and heating at 75 °C for two weeks.  
A control sample containing a G1 dendron was also exposed to the same conditions.   
Upon cooling, the solution is added to approximately 1 mL of water, and 3M NaOH is 
added dropwise while swirling the solution until a pH of approximately 7 is reached.  
The water is removed by rotary evaporation, the solid is washed with methanol, and the 
salts are removed by filtration. 
Powdered chitosan was synthesized using methods of Tsubokawa, et al.118  
Samples of chitosan flakes (3.0 g) of low, medium, and high molecular weights are 
placed in 300 mL of water and 30 mL of 0.5 M HCl is added.  The mixture is allowed to 
stir for about one hour at which time the solution is filtered to remove any undissolved 
material, and 10 M NaOH is added until a precipitate forms and the solution reaches pH 
10.  The precipitate is then filtered, washed with approximately 300 mL water, or until 
the filtrate is neutral, washed with approximately 100 mL of acetone, and dried under 
vacuum.   
Atrazine Sequestration.  Thirty milligrams of each sample is added to 
individual 5 mL fritted syringes containing 3 mL of 100 ppb aqueous atrazine solution.  
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This is done in triplicate.  The syringes are capped and shaken for 24 h. using a wrist 
action shaker.  The solutions are collected, filtered through 0.2 μm syringe filters, and 
analyzed for the amount of atrazine remaining in solution by liquid chromatography 
(LC)-MS at the Laboratory for Biological Mass Spectrometry at Texas A&M University. 
Adsorption─Desorption Experiments.  The chitosan samples from the atrazine 
study were placed in glass vials, 5 mL of acetone is added to each vial, and the vials 
were shaken for 24 h using a wrist action shaker.  The solutions were collected and 
filtered through 0.22 μm syringe filters.  The solvent was evaporated, and the samples 
are redissolved in distilled water.  The samples were then analyzed for the amount of 
atrazine remaining by UV─Vis absorption at 221 nm, compared to a standard calibration 
curve.  The results of these studies were inconclusive. 
Results and Discussion 
Nomenclature.  For clarity, the grafted polymers on chitosan are referred to by 
their size using the common term "generation" abbreviated "G" with a number "1-3".  To 
distinguish between the dichlorotriazine and piperazine adducts, we use the 
abbreviations "Cl" and "NH" respectively.    
Synthesis and Characterization.  The synthesis of the grafted polymers is 
shown in Scheme 17.  For clarity, the idealized structure, a dendrimer graft, is shown.  
These grafts are grown stepwise in an iterative fashion such that reaction of chitosan 
with cyanuric chloride will produce some amount of dichlorotriazine, G1-Cl, which 
upon reaction with piperazine produces G1-NH.  Chitosan flakes and powders were 
treated similarly.  These materials were suspended in tetrahydrofuran and incubated with 
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an excess of reagent. The triazine chemistry was performed at 0 °C, a protocol adopted 
from earlier work on other supports, which we presume reduces the rate of hydrolysis or 
undesirable side reactions with the hydroxyl groups of the biopolymer that could lead to 
crosslinking (indicated with arrows).  Reaction of the dichlorotriazine with an excess 
piperazine was performed at 25 °C, a temperature at which solution phase substitutions 
proceed readily.   
 
Scheme 17.  Synthesis of the desired grafts 
  
  
Possible cross-linking of chitosan chains and structural defects from incomplete 
substitutions, especially as steric hindrance increased, were two difficulties encountered 
by using divergent dendron synthesis.  The divergent strategy adopted here significantly 
reduces the burden of synthesis in comparison with the convergent strategy, which 
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requires that the dendrimer be first prepared in solution and then grafted to the support.  
When both strategies were compared for silica gel supported materials, it was found that 
materials afforded by the divergent approach were better sequesterants.115  Both issues 
suggest that these materials obtained by divergent pathway are of significantly greater 
interest.   
  While the chemistry is pedestrian, monitoring these reactions proved to be 
remarkably challenging.  While chitosan shows some solubility in aqueous acetic acid, 
the modifications intended cannot be run under these conditions as hydrolysis actively 
competes with nucleophilic aromatic substitution. Unfortunately, upon modification, the 
solubility of the graft products is further diminished such that solution phase analysis 
including NMR spectroscopy was not possible.  X-ray photoelectron spectroscopy 
proved to be highly dependent on sample preparation and surface non-uniformity.  
Thermogravimetric analysis which is often useful for organic-inorganic hybrid materials 
gave no quantitative information due to the presence of only organic material.  
Differences in the weight loss curves did indicate a change in the structure of the 
materials, however.  Acid hydrolysis of the chitosan adducts could be effected, but no 
useful structural information was available presumably due to the low abundance of 
material due to our strategy of surface derivatization.  When identical conditions were 
employed for a melamine dendron with a similar structure, no decomposition was 
observed. 
 Colorimetric analysis, however, proved remarkably useful.  Figure 6 shows the 
result of treatment of these materials with a solution of ninhydrin affords a dark color 
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(purple or brown) in the presence of amines.  The solution remains yellow in the absence 
of amines.  The iterative nature of the synthesis, masking amines with dichlorotriazines 
and then providing secondary amines of piperazine, in principle should provide an 
oscillating positive and negative colorimetric test.  Numerically quantifying the test is 
difficult because the dye absorbs to the chitosan flakes. 
 
 
Figure 6.  Colorimetric analysis of derivatized chitosan flakes.   
A) Chitosan.  B) G1-Cl.  C) G1-NH.  D)  G2-Cl.  E) G2-NH.  F)  G3-Cl.  G)  G3-NH. 
 
 Indirectly, the colorimetric tests reveal limitations in the synthesis.  That is, the 
outline synthesis described in Scheme 17 where perfectly branched materials are 
prepared is not entirely accurate.  Instead, incomplete reaction likely occurs, especially 
at generation 3 as evident from the pink-tinge that the solution of G3-Cl affords: free 
amines are present.  As thorough washing is part of the protocol, we believe that the 
color is a result of the structural defects similar to those observed with the silica gel 
supported materials.115  For the powdered chitosan adducts, the ninhydrin results were 
41 
similar, but it appeared that the reaction may have proceeded more readily to completion 
as evidenced by an absence of a pink or purple hue for the G3-Cl powdered material as 
seen in Figure 7. 
 
 
Figure 7.  Colorimetric analysis of powdered materials.   
A) Chitosan.  B) G1-Cl.  C) G1-NH.  D)  G2-Cl.  E) G2-NH.  F)  G3-Cl.  G)  G3-NH. 
  
 
The materials were also subjected to attenuated total internal reflection Fourier 
transform infrared spectroscopy (ATR-FTIR).  Bands in the region of 1400-1600 cm-1 
are introduced after the first reaction sequence.  These bands are attributed to the triazine 
and melamine-type structures on the chitosan.  Evidence of incomplete growth is given 
by the less pronounced changes in this region as the dendron growth progresses to higher 
generations.  The iterative nature of the synthesis is revealed with the intensity of the 
broad absorption band centered at 3400 cm-1 attributed to N-H and O-H stretching.  The 
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band is more pronounced in chitosan, G1-NH, G2-NH and G3-NH materials than in the 
corresponding dichlorotriazines, G1-Cl, G2-Cl, and G3-Cl.  (Figure 8) 
 
 
Figure 8.  ATR-IR spectra of the materials 
 
Atrazine Sequestration.  The hypothesis for the presence of nucleophilic, 
constrained secondary amines displayed on chitosan was born out in sequestration 
studies.  Figure 9 summarizes the results of batch equilibration studies performed using 
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chitosan flakes of low, medium and high molecular weights.  Suspended chitosan, before 
or after washing with aqueous sodium hydroxide, shows only modest sequestration 
potential.  Upon installation of the dichlorotriazine, G1-Cl, the sequestration potential 
drops off precipitously due presumably to the absence of nucleophilic amines.  This 
result is consistent with other studies, but somewhat surprising given that we might 
expect that the hydrophobic character of atrazine, as evident from its low solubility in 
water, would promote adsorption onto the more hydrophobic support.  Upon installation 
of the piperazine groups, all three supports sequester more than 99% of the atrazine from 
a 100 ppb solution as evaluated by LC-MS.  This activity drops off as the amines are 
masked with triazines of G2-Cl, but remains greater than unmodified chitosan or G1-Cl.  
We attribute this to the onset of hydrophobic character, as colorimetric studies suggest a 
lack of nucleophilic amines.  This trend continues through the subsequent materials.  
Quantifying results from samples derived from powdered chitosan was not possible 
using LC-MS due to the presence of materials sufficiently sized to foul the instrument, 
but small enough to elute through dialysis membranes.  We believe this material is 
chitosan derived from the powdering process.  Efforts to wash these samples 
continuously for one week did not provide remedy. 
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Figure 9.  Atrazine sequestration by the materials using low (white), medium (gray) and high (black) 
molecular weight chitosan flakes 
   
Conclusions 
Chitosan, which has many potential uses for environmental remediation, can be 
modified to perform efficient sequestration of triazine herbicides such as atrazine.  
Dendritic molecules, such as dendrimers based on melamine, can be synthesized on solid 
chitosan flakes.  The dendrimers increase the number of amine groups on the surface of 
the chitosan and increase the amount of atrazine sequestered.  The use of chitosan as a 
solid support has an advantage of its ability to be woven into fabric and possibly coupled 
with erosion control for sequestration in the field.  The combination of chitosan’s ability 
to adsorb materials such as metals and dyes with pesticides leads to many future possible 
uses of chitosan for remediation and pollution control. 
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CHAPTER IV 
SYNTHESIS OF MELAMINE DENDRIMERS FOR DRUG DELIVERY 
APPLICATIONS 
 
Introduction 
 The term “magic bullet” was first introduced by Paul Ehrlich.  Ehrlich’s work 
with immunology led to his receiving the Nobel Prize in Physiology or Medicine in 
1908.  Among his contributions was the belief that compounds with specific structures 
could be found which would recognize and bind a specific disease-causing target in an 
organism to provide therapeutic action to this target without causing harm to the 
organism itself – a magic bullet.119  Among many other accomplishments, Ehrlich’s 
work contributed to the establishment of chemotherapeutic techniques.120 
Pharmacologically active polymers have been recognized as important targets for 
decades, especially in the field of cancer therapeutics due to the non-specificity of many 
drugs.  These “magic bullets” could enter tumor cells and deliver a payload of drug 
without harming the individual.  In 1975, Ringsdorf defined the ideal structure and 
properties of polymeric drug agents.121  He described a carrier with a biostable or 
biodegradable backbone comprised of three parts.  First, the polymer carrier should have 
a group that renders the macromolecule soluble and nontoxic.  The second group is for 
the attachment of the drug, which would be performed under mild conditions and would 
incorporate a spacer to separate the drug from the polymer. These conditions would need 
to be met in order to ensure there would be no adverse effects on the drug’s biological 
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activity once attached to the polymeric carrier.  The linkage between the polymer and the 
drug would need to be stable under normal body conditions but able to release the drug 
rapidly by hydrolysis or enzymatic processes once the site of action is reached.  The 
third group would transport the entire carrier to the target cells by use of a homing 
device or through nonspecific enhancement of cellular-uptake. 
 Polymers, and therefore polymer drug conjugates, enter cell membranes by 
endocytosis rather than by diffusion.  The macromolecules are engulfed by the plasma 
membrane and form endosomes which can fuse with enzyme-containing lysosomes.  
Provided the linker connecting the drug and carrier meets the aforementioned conditions, 
the linker may be cleaved to release the drug either enzymatically or by hydrolysis 
induced by the decrease in pH from 7.4 in the cytoplasm to pH 5 found in the lysosome.  
 Macromolecules show specificity to tumor cells due to a phenomenon known as 
the enhanced permeability and retention effect (EPR).122  Maeda and co-workers coined 
the term EPR effect in 1986.123  They attributed the EPR effect to two main factors:  
leaky tumor vessels allowing entry of macromolecules, an activity which is not usually 
allowed in normal tissues, and an ineffective tumor lymphatic drainage system which 
prevents clearance of the macromolecules and promotes their accumulation. (Figure 10) 
 The typical value for the molecular weight of macromolecules which can exploit 
the EPR effect is greater than 40 kDa,124 but studies have shown polymers with 
molecular weights between 20 and 800 kDa are able to access tumors.  Studies of non-
uniform accumulation of polymers in tumor tissue demonstrate that the threshold of 
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vascular permeability actually varies with polymer architecture, tumor size and type, and 
even vessel to vessel in the local microenvironment of the tumor.125 
 
 
Figure 10.  The EPR effect. 
  
 As mentioned in Chapter I, dendrimers are highly branched, symmetric, synthetic 
polymers emanating from a central core.  These multivalent molecules are globular in 
shape, monodisperse, and allow control of molecular weight, surface groups, and interior 
groups.28-31  Due to these properties, dendrimers are attractive targets for drug delivery 
agents.122,126-134  Figure 11 shows the possible uses of the multivalency of dendrimers.  
Synthetic manipulations to the functional groups in the core of the dendrimers would 
facilitate noncovalent encapsulation of drugs in the interior.  Also, covalent attachment 
of solubilizing groups, targeting moieties, and drugs to the periphery of dendrimers is 
possible with modifications of the surface groups.   
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Figure 11. Possible functionalization of a dendritic drug delivery agent. 
 
 Noncovalent encapsulation of drugs with dendrimers can be accomplished using 
hydrogen bonding, hydrophobic, or electrostatic interactions between the guests and 
host.135  One method of encapsulation is the construction of dendritic ‘unimolecular 
micelles’.136-139 Conventional polymeric micelles are amphiphilic block copolymers 
which form thermodynamic aggregates in proper solvents above the critical micelle 
concentration (c.m.c.).  This property is also the limiting factor in micellar drug delivery 
applications.  Under physiological conditions, the concentration may drop below the 
c.m.c. causing dissociation of the micelle into free polymer chains.  With unimolecular 
micelles, the hydrophobic and hydrophilic segments are covalently bound together 
imparting stability to the micellar structure.  Hydrophobic drugs can be solubilized in the 
hydrophobic core of the dendrimer while the hydrophilic portion, usually polyethylene 
glycol (PEG) chains, on the periphery solubilizes the entire carrier.131 
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 Interactions between dendrimers and guests to afford encapsulation have been 
exploited by many groups.140-151  Twyman, et al. synthesized water-soluble, hydroxyl 
terminated poly(amido amine) (PAMAM) dendrimers capable of solubilizing several 
small, acidic, hydrophobic model compounds including benzoic acid and salicylic acid.  
The complexes were stable at pH 7, but under acidic conditions, precipitation of the 
model hydrophobic compounds occurred.  It was thought that protonation of the internal 
tertiary amines of the dendrimer interrupted the noncovalent interactions with the acidic 
guests causing this dissociation.152 
 The effect of pH on dendrimer structure has also been investigated.  Newkome 
and co-workers found that for a series of acid terminated cascade dendrimers of 
generation 1-5, the hydrodynamic radii decreased as pH decreased.153  While for 
PAMAM dendrimers, a simulation study of generations 0-11 found the radius of 
gyration to increase with decreasing pH due to protonation of primary amines and 
interior tertiary amines.  As the amines are protonated, electrostatic repulsions are 
created between the primary and tertiary amine sites pushing the arms apart and out.  
The calculated radii of gyration were in good agreement with the available SAXS and 
SANS data in this study.  The structure was also shown to be more open to solvent as pH 
decreased allowing water molecules to more easily penetrate the interior of the 
dendrimer.154  A study by Turro and co-workers showed that the binding specificity of 
PAMAM dendrimers is affected by pH.  At neutral or slightly acidic pH, 2-naphthol has 
the ability to hydrogen bond to interior tertiary amines, but as the pH is lowered, 
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protonation of the amines coupled with an opening of the interior of the dendrimer 
causes a reduction in binding until eventually no binding occurs.155   
Simanek and co-workers have reported the synthesis of dendrimers based on 
melamine for noncovalent encapsulation of anti-cancer agents.  Zhang, et al. reported the 
ability of a melamine dendrimer to efficiently encapsulate 10-hydroxycaptothecin and a 
novel bisindolemethane.  However, encapsulation efforts between indomethacin, an 
anionic drug, and the cationic dendrimer provided a precipitated complex rather than 
facilitating solubilization of the molecule, and another anionic drug, methotrexate, 
experienced neither a solubilization increase nor a precipitation event.  These studies 
suggest that the composition of the dendrimer plays an important role in the 
encapsulation ability.156  Subsequent efforts in this laboratory reported by Neerman, et 
al. show that a variant of this dendrimer is able to effectively solubilize and reduce the 
hepatotoxicity of methotrexate and 6-mercaptopurine.157   
Covalent attachment of drugs to dendrimers is the second method for the 
preparation of drug-macromolecule complexes.  Fréchet and co-workers synthesized 
have synthesized several structures to this end.   PEG-poly(aryl ether) dendrimers were 
synthesized for the attachment of model drug compounds.  The PEG chains were 
selected as the solubilizing groups.  The model compounds cholesterol, phenylalanine, 
and tryptophan were conjugated to the periphery of the dendrimer to illustrate the 
conjugation of drugs with various functionalities:  hydroxyl, carboxylic acid, and amino 
groups, respectively.158  A second polyether dendrimer was synthesized with terminal 
ester groups.  The esters were converted to hydrazides to conjugate folate or 
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methotrexate residues to the periphery.159   A three-arm poly(ethylene oxide) (PEO) star 
with terminal polyester dendrons was synthesized, also, and the anti-cancer drug 
doxorubicin was covalently bound to the periphery of the dendritic wedges by the 
formation of acid labile hydrazones. The compound was evaluated for in vitro and in 
vivo activity showing promising activity that should further advance the development of 
such macromolecular drug conjugates.134,160 
 Another example of covalent conjugation is Baker’s work in which antibodies 
are attached to dendrimers for use as targeting moieties.161,162  Monoclonal antibodies 
show promise for use as cancer-targeting agents because the surface antigens expressed 
by tumor cells are specific to the cancer or are overexpressed on cancerous cells.  Efforts 
to form immunoconjugates in which a drug is directly conjugated to the antibody found 
limitations such as reduced drug activity or reduced antibody affinity.  Conjugation of 
the drug and the antibody to a macromolecular carrier may be useful for overcoming 
these limitations.162 
 Simanek and co-workers have reported the synthesis of dendrimers based on 
melamine with incorporation of multiple orthogonal functional groups.  The differential 
reactivity of the primary building block of these dendrimers, cyanuric chloride, allows 
for incorporation of different groups with each substitution if desired, as discussed in 
Chapter I.  The work of Steffensen and Simanek provided a dendrimer with five 
orthogonally reactive groups.38  Modifications of this dendrimer allows for a multitude 
of possibilities.  The incorporation of peptides to increase cellular uptake, small 
molecules such as biotin to increase binding, dyes to follow cellular uptake, or addition 
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of an alkyne to partake in ‘click chemistry’ are but a few of the possiblites set out by this 
multifunctional dendrimer.  Lim and Simanek followed suit with a similar dendrimer 
containing four functional groups which could be used for the conjugation of drugs, 
PEGylation to enhance solubility and biocompatibility, incorporation of “tags” to 
monitor biodistribution, and attachment of targeting moieties.163  
Another major aspect of dendrimers for drug delivery applications is for imaging. 
Dendrimers are of great interest as macromolecular carriers of contrast agents for MRI, 
scintigraphy, ultrasound, and X-ray, including computed tomography (CT).164,165  
Contrast agents are used to modify the response of the signal produced to improve the 
sensitivity and specificity of the imaging method being employed.  Ideal contrast agents 
have little interaction with the organism and are well tolerated.164  However, this is not 
always the case.  As said by Dr. Milos Sovak in The Handbook of Experimental 
Pharmacology-Radiocontrast Agents, “Contrast media are drugs by default….The 
position of CM in pharmacology is unique.  First, there is the unusual requirement of 
biological inertness.  An ideal CM should be completely inert, i.e., stable, not 
pharmacologically active, and efficiently and innocuously excretable.  Because they fail 
to meet these requirements, CM must be considered drugs.”166   
Contrast agents have been used since shortly after the discovery of X-rays by C. 
W. Roentgen in 1895.  Iodine is often the element of choice for contrast agents due to 
the fact that iodinated contrast agents produce positive contrast during an X-ray.   The 
presence of the higher atomic weight atoms compared to the atoms in the biological 
tissue causes the attenuation of the radiation to be higher for the contrast agent than the 
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surrounding tissue.  The first contrast agent was NaI and was fairly toxic.  Subsequent 
research efforts attempted to mask the iodine to reduce toxicity by binding the iodine to 
an organic moiety.  The first commercially available contrast agent was introduced in 
1929, uroselectan, which contained one iodine atom bound to a non-aromatic six-
membered ring.  Subsequent contrast agents utilized benzene rings as the iodine carriers 
to incorporate 2 or 3 iodine atoms per molecule.  Contrast agents then progressed from 
ionic monomers to nonionic monomers and eventually to dimers of the ionic or nonionic 
compounds.  Most of the present-day contrast agents are nonionic monomers containing 
polyol segments.  The non-iodine portion of the contrast agent serves to increase 
solubility, form stable covalent bonds to iodine, and mask the iodine atoms making them 
“biologically invisible” to the body.164,167 (Chart 5) 
 
Chart 5.  Commonly used X-ray contrast agents. 
 
 
For CT imaging, large amounts of contrast agent are needed, approximately 30-
50 g of iodine which is equivalent to about 70-120 g of drug.  The solutions injected into 
the patients are very concentrated, usually about 200-400 mg/mL for a total volume of 
100-150 mL.  This creates high osmotic potentials causing more toxicity effects.164,168  
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As shown in Figure 12 below, the contrast agent creates an increase in plasma osmolality 
in the blood stream and extravascular water is drawn into the vessels.  At the same time, 
the hypertonicity of the plasma causes water within red blood cells to be drawn into the 
vascular space as well.  This can cause toxic effects in the body, in addition to diluting 
the concentration of contrast agent.166 
 
 
Figure 12.  Effect of injection of contrast medium with high osmolality into bloodstream  
 
More than 600 milion X-ray examinations are conducted annually with 
approximately 75 million of these employing contrast agents.  Approximately 1% of the 
patients receiving contrast agents experience adverse reactions which is equivalent to 
750,000 patients per year.  Adverse reactions can range from mild reactions including 
nausea and itching to severe reactions including anaphylactic shock or renal failure.  
Severe reactions occur in 0.01%-0.04% or 7,000-30,000 patients each year.168  But 
adverse reactions have been shown to more likely develop in patients with a history of 
allergy to contrast media, asthma, or those who are medically unstable or debilitated.  
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Also, the introduction of low-osmolality agents has caused a significant decrease in non-
fatal reactions and renal impairment.169 
Another factor to consider with currently used contrast agents is extravasation 
which causes the contrast agent to diffuse into the extracellular space.  (Figure 13)  This 
occurs because blood vessels contain pores approximately 12 nm in diameter through 
which small molecules can easily pass.  Molecules larger than approximately 20 kDa 
cannot pass through these pores. Extravasation causes the contrast media to be rapidly 
distributed throughout the body after injection.  This results in an extremely short 
imaging window and limits the possibility of accurate imaging to the first passage of the 
agent through the area of interest.164   
The employment of macromolecular contrast agents would reduce the dosage 
needed due to longer circulation times and lack of extravasation.  In addition, 
macromolecules would reduce the osmotic potential, thereby reducing toxicity of the 
contrast agents, by increasing the number of iodine atoms on a molecule.  
Macromolecular agents could also aid in the detection of tumors due to the increased 
accumulation in tumor tissue caused by the EPR effect.164 
 
 
Figure 13.  Extravasation of contrast agent out of capillary into extracellular space (1) during bolus, (2) 
shortly after bolus, and (3) a longer period after bolus.  
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 Polymeric and dendritic contrast agent delivery systems have been reported but 
each has its drawbacks, whether it be synthetic problems such as drug uniformity, 
reproducibility, or purity of the compounds produced, or the economic feasibility of the 
synthesis on a large scale.164,165,167,170-172  A few other examples have come close to an 
ideal structure.  Brasch and co-workers have synthesized a macromolecular iodinated 
contrast agent having a PEG core and lysine dendrons on both ends.  This method allows 
for a monodisperse molecule with a predetermined weight.173  The molecule with 
molecular weight of approximately 40 kDa and an iodine content of 27% by weight has 
been shown to have good activity as a contrast agent and exhibits the ability to 
characterize tumor vasculature when compared to a commonly used small molecule 
contrast agent, iohexol (Omnipaque).174  Lysine dendrimers, however, are not readily 
amenable to large-scale, economically cost-efficient syntheses.   
Another example which was synthesized by Le Lem, et al. is called P743.175,176  
This monodisperse, dendritic, iodinated macromolecule has a molecular weight of 
approximately 13 kDa and an iodine content of 35% by weight and has been shown to 
have lower attenuation but longer circulation times than the standard contrast agent 
iobitridol.177-179  Data reported for tumor studies were a bit inconclusive stating that the 
use of iodinated contrast agents to image tumors is feasible.180  Since this molecule is 
slightly below the value normally associated with the EPR effect, perhaps the activity 
was not marked enough to warrant a conclusive study.   
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Experimental 
Materials and Methods.  ACS-grade solvents were used for all the synthetic 
preparations. Distilled and deionized water was obtained in-house.  2,2’-
Oxybis(ethylamine) was purchased from TCI Organic Chemicals, and 2,4-diiodoaniline 
was purchased from Spectra Group Limited, Inc.  NHS-m-dPEG of molecular weight 
1214 was purchased from Quanta BioDesign, Ltd., and m-PEG-SPA-2000 was 
purchased from Nektar Therapeutics.  All other reagents and solvents were purchased 
from Acros Organics or Aldrich Chemical Co. and were used without further 
purification.  1H NMR and proton decoupled 13C NMR spectra were acquired on a 
Varian 300 MHz spectrometer using CDCl3, CD3OD, Acetone-d6, or D2O.  NMR 
chemical shifts are listed relative to tetramethylsilane in parts per million (ppm) and 
were referenced to the residual proton or carbon peak of the solvent.  MS analysis was 
performed by the Laboratory for Biological Mass Spectrometry at Texas A&M 
University.  Elemental analysis was performed by Atlantic Microlab, Inc. in Norcross, 
GA.  CHN analysis was performed by combustion using automatic analyzers.  Chlorine 
and iodine analysis was performed by flask combustion followed by ion 
chromatography.  Analysis gave percent by weight determination.  Gel Permeation 
Chromatography (GPC) data was obtained using a multi-detector system with a Visco-
GEL, mixed-bed, I-MBMMW-3078 column 7.8 mm x 30 cm with a flow rate of 1.000 
mL/min, injection volume of 100 μL, detector temp. of 27.0 °C, and column temp. of 
30.0 °C using HPLC-grade THF as the mobile phase.  The detectors employed were 
Viscotek:  UV/Vis detector model VE3210 with readings taken at 265 nm, RI detector 
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model VE3580, and RALS/LALS/DP model 270 dual detector.  Data was viewed and 
manipulated using OmniSEC software.  Thin-layer chromatography was performed 
using EMD silica gel 60 F254 pre-coated glass plates (0.25 mm), and preparative 
chromatography was performed using EMD silica gel 60 (0.040 mm particle size). 
Isosteric Dendrimer Nomenclature.  For compounds having the structure 
RHN(CH2)2X(CH2)2NHR’ with R and R’ being either a Hydrogen or other substituent 
and X being a Boc-protected amine, oxy, or methylene group, compounds will be 
denoted as N, O, or C, respectively.   
Isosteric Dendrimer Synthesis and Characterization.   
Compound 1.  A solution of diethylene triamine (3.16 mL, 29 mmol) in 58 mL of 
DCM (0.5 M) was placed in an ice bath, and a solution of ethyl trifluoroacetate (7.28 
mL, 61 mmol) in 30.5 mL DCM (2M) was added dropwise.  The solution was stirred at 
0 °C for 30 min. then further allowed to stir for an hour at room temperature.  At this 
time, a solution of triethylamine (8.51 mL, 61 mmol) and di-tert-butyl dicarbonate 
(13.32 g, 61 mmol) in 30.5 mL DCM (2 M) was added dropwise.  The reaction was 
allowed to stir at room temperature for 18 hours.  Then, the reaction mixture was 
extracted with saturated sodium bicarbonate (2 x 150 mL), dried over magnesium 
sulfate, and rotovapped to one third of the volume.  At this point, the same volume of 
hexanes was added and the solution was placed in the freezer for 18 hours.  The white 
crystalline product was filtered, washed with hexanes, and dried under vacuum.  Yield:  
7.60 g (66%).  1H NMR (300 MHz, CDCl3) δ:  7.74 (s, NH), 7.22 (s, NH), 3.49 (s, 8H), 
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1.44 (s, 9H).  13C NMR (75.5 MHz, CDCl3) δ:  157.10, 117.63, 113.82, 99.84, 82.06, 
47.16, 46.08, 40.20, 39.06, 28.01.  ESI-MS (m/z):  calcd 395.1280,  found 396.1359 
[M+H]+. 
Compound 2.  1 (1.02 g, 2.6 mmol) was dissolved in 14 mL ethanol and 3M 
NaOH (10 mL, 30 mmol) was added.  The solution was stirred for 18 hours, rotovapped 
to remove the ethanol, and the residue was extracted with DCM (3 x 100 mL).  Then, the 
sample was dried over magnesium sulfate, rotovapped, and dried under vacuum.  Yield: 
429 mg (82%).  1H NMR (300 MHz, CDCl3) δ:  3.17 (s, br, 4H), 2.73 (t, J=6.46, 4H), 
1.41 (s, NH) 1.35 (m, 9H).  13C NMR (75.5 MHz, CDCl3) δ:  155.88, 79.46, 50.49, 
40.50, 28.22.  ESI-MS (m/z):  calcd 203.1634, found 204.1516 [M+H]+, 226.1421 
[M+Na]+ 
Compound 3.  1,1’-carbonyl diimidazole (3.21 g, 19.8 mmol) and tert-butanol 
(2.0 mL, 19.9 mmol) were dissolved in 70 mL toluene in a pressure flask.  The solution 
was heated at 65 °C for three hours.  Upon cooling, diethylene triamine (1.1 mL, 9.9 
mmol) was added, and the solution was again heated to 65 °C for 3 hours.  The mixture 
was then cooled, transferred to a round bottom flask, rotovapped, dissolved in DCM, and 
extracted with water (3 x 100 mL).  The combined organic layers were dried over 
sodium sulfate, rotovapped, and dried under vacuum.  Yield:  1.63 g (54%).  1H NMR 
(300 MHz, CDCl3) δ:  5.02 (s, NH), 3.17 (q, J=5.78, 2H), 2.68 (t, J=5.78, 2H), 1.87 (s, 
NH), 1.40 (s, 9H).  13C NMR (75.5 MHz, CDCl3) δ:  156.17, 79.17, 48.75, 40.23, 40.21, 
28.35.   ESI-MS (m/z):  calcd 303.2158, found 304.2139 [M+H]+. 
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Compound 4.  To a cold solution of cyanuric chloride (347 mg, 1.9 mmol) and 
Hünig’s Base (0.75 mL, 4.3 mmol) in 10 mL THF, a solution of 3 (1.13 g,  3.7 mmol) in 
10 mL THF was added.  The reaction was stirred at 0 °C for about 3 hours and then 
allowed to warm to room temperature and stir for 18 hours.  The solution was filtered, 
and the filtrate was rotovapped, dissolved in DCM, extracted with water (3x 100 mL), 
dried over magnesium sulfate, and rotovapped.  The product was then purified by silica 
gel column chromatography using a gradient of DCM—4:1 (DCM:EtOAc).  Yield:  1.05 
g (79%).  1H NMR (300 MHz, CDCl3) δ:  5.62 (s, NH), 5.21 (s, NH), 3.58 (m, 8H), 3.25 
(m, 8H), 1.36 (m, 36H).  13C NMR (75.5 MHz, CDCl3) δ:  168.82, 165.15, 156.17, 
79.17, 79.10, 78.96, 47.86, 47.31, 47.12, 39.37, 38.57, 37.55, 28.37, 28.23.  MALDI-MS 
(m/z):  calcd 717.3940, found 718.3904 [M+H]+, 740.3672, [M+Na]+. 
Compound 5-N.  2 (137 mg, 0.7 mmol) and Hünig’s Base (0.1 mL, 0.6 mmol) 
were added to a solution of 4 (219 mg, 0.3 mmol) in 3 mL THF in a pressure flask.  The 
reaction was stirred at 70 °C for 48 hours, and upon cooling, the solution was filtered.  
The filtrate was then rotovapped, dissolved in DCM, extracted with water (3 x 50 mL), 
dried over magnesium sulfate, and rotovapped.  The product was then purified using 
silica gel column chromatography with a 19:1 (DCM: MeOH) to MeOH gradient.  
Yield:  178 mg (66%).  1H NMR (300 MHz, CDCl3) δ:  5.59 (s, NH), 5.44 (s, NH), 3.57 
(s, 8H), 3.42 (s, 4H), 3.27 (d, J=4.95, 8H), 3.11 (s, 4H), 2.93 (s, NH), 1.40 (m, 45H).  
13C NMR (75.5 MHz, CDCl3) δ:  168.62, 165.67, 165.62, 156.22, 79.14, 79.10, 47.45, 
47.37, 46.83, 40.05, 38.45, 28.43.  MALDI-MS (m/z):  cacld 884.5807, found 885.6851 
[M+H]+, 907.6590 [M+Na]+ , 923.6322 [M + K]+. 
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Compound 5-O.  Oxy-ethylene diamine (0.16 mL, 1.4 mmol) and Hünig’s Base 
(0.25 mL, 1.5 mmol) was added to a solution of 4 (524 mg, 0.7 mmol) in 7 mL THF in a 
pressure flask.  The reaction was stirred at 70 °C for 48 hours, and upon cooling, the 
solution was filtered.  The filtrate was then rotovapped, dissolved in DCM, extracted 
with water (3 x 50 mL), dried over magnesium sulfate, and rotovapped.  The product 
was then purified using silica gel column chromatography with a 19:1 (DCM: MeOH) to 
MeOH gradient.  Yield:  370 mg (65%).  1H NMR (300 MHz, CDCl3) δ:  5.95, (s, NH), 
5.70 (s, NH), 5.59 (s, NH), 5.23 (s, NH), 3.57 (m, 10H), 3.48 (s, 4H), 3.27 (s, 8H), 2.86 
(s, 2H), 2.19 (s, NH), 1.38 (s, 36H).  13C NMR (75.5 MHz, CDCl3) δ:  165.71, 165.48, 
156.11, 79.07, 78.84, 72.85, 69.74, 47.32, 46.57, 41.58, 40.45, 38.27, 28.35.  MALDI-
MS (m/z):  cacld 785.5123, found 786.4912 [M+H]+, 808.4731 [M+Na]+, 824.4530 
[M+K]+. 
Compound 5-C.  Pentane diamine (0.17 mL, 1.4 mmol) and Hünig’s Base (0.25 
mL, 1.4 mmol) was added to a solution of 4 (520 mg, 0.7 mmol) in 7 mL THF in a 
pressure flask.  The reaction was stirred at 70 °C for 48 hours, and upon cooling, the 
solution was filtered.  The filtrate was then rotovapped, dissolved in DCM, extracted 
with water (3 x 50 mL), dried over magnesium sulfate, and rotovapped.  The product 
was then purified using silica gel column chromatography with a 19:1 (DCM: MeOH) to 
MeOH gradient.  Yield:  370 mg (65% Yield).  1H NMR (300 MHz, CDCl3) δ:  6.05 (s, 
NH), 5.77 (s, NH), 5.62 (s, NH), 4.91 (s, NH), 3.53 (m, 8H), 3.30 (m, 10H), 2.66 (s, 2H), 
2.01 (s, NH), 1.53 (m, 4H), 1.37 (s, br, 38H).  13C NMR (75.5 MHz, CDCl3) δ:  165.70, 
165.55, 165.47, 156.121, 79.00, 78.74, 47.29, 46.50, 41.72, 40.47, 40.38, 38.26, 38.20, 
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32.92, 30.94, 29.43, 28.36, 24.11.  MALDI-MS (m/z):  cacld 783.5331, found 784.6586 
[M+H]+, 806.6439 [M+Na]+, 822.6312 [M+K]+. 
Compound 6-N.  5-N (215 mg, 0.2 mmol) was added to a cold solution of 
cyanuric chloride (18 mg, 0.09 mmol) and Hünig’s Base (0.04 mL, 0.2 mmol) in 3 mL 
THF.  The reaction was stirred at 0 °C for about 3 hours and then allowed to warm to 
room temperature and stir for 18 hours.  The solution was filtered, and the filtrate was 
rotovapped, dissolved in DCM, extracted with water (3 x 25 mL), dried over magnesium 
sulfate, and rotovapped.  The product was then purified using silica gel column 
chromatography with a gradient of DCM—1:1:1% (DCM:EtOAc:MeOH). Yield:  153 
mg (84%).  1H NMR (300 MHz, CDCl3) δ:  6.15 (s, NH), 5.79 (s, NH), 5.57 (s, NH), 
5.32 (s, NH), 3.56-3.29 (br, 48H), 1.40 (s, 90H).  13C NMR (75.5 MHz, CDCl3) δ:  
165.72, 165.40, 164.83, 156.25, 155.42, 78.13, 48.75, 47.40, 45.90, 39.92, 28.46.  
MALDI-MS (m/z):  cacld 1880.1239, found 1882.3485, [M+H]+, 1904.3252 [M+Na]+, 
1919.2969 [M+K]+. 
Compound 6-O.  5-O (207 mg, 0.3 mmol) was added to a cold solution of 
cyanuric chloride (25 mg, 0.1 mmol) and Hünig’s Base (0.07 mL, 0.4 mmol) in 2 mL 
THF.  The reaction was stirred at 0 °C for about 3 hours and then allowed to warm to 
room temperature and stir for 18 hours.  The solution was filtered, and the filtrate was 
rotovapped, dissolved in DCM, extracted with water (3 x 25 mL), dried over magnesium 
sulfate, and rotovapped.  The product was then purified using silica gel column 
chromatography with a gradient of DCM—1:1:1% (DCM:EtOAc:MeOH).  Yield:  151 
mg (34%).  1H NMR (300 MHz, CDCl3) δ:  5.83 (s, NH), 5.63 (s, NH), 5.26 (s, NH), 
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3.56 (s, 32H), 3.26 (s, 16H), 1.38 (s, 72H).  13C NMR (75.5 MHz, CDCl3) δ:  165.56, 
165.61, 165.47, 156.16, 79.11, 79.05, 69.82, 69.73, 69.51, 69.09, 47.41, 47.36, 46.61, 
40.57, 40.31, 40.26, 38.35, 38.22, 28.49, 28.32, 28.22.  MALDI-MS (m/z):  calcd 
1681.9871, found 1683.3053 [M+H]+, 1705.2670 [M+Na]+, 1721.2533 [M+K]+. 
Compound 6-C.  5-C (187 mg, 0.2 mmol) was added to a cold solution of 
cyanuric chloride (24 mg, 0.1 mmol) and Hünig’s Base (0.07 mL, 0.4 mmol) in 2 mL 
THF.  The reaction was stirred at 0 °C for about 3 hours and then allowed to warm to 
room temperature and stir for 18 hours.  The solution was filtered, and the filtrate was 
rotovapped, dissolved in DCM, extracted with water (3 x 25 mL), dried over magnesium 
sulfate, and rotovapped.  The product was then purified using silica gel column 
chromatography with a gradient of DCM—1:1 (DCM:EtOAc).  Yield:  132 mg (67%).  
1H NMR (300 MHz, CDCl3) δ:  5.85 (s, NH), 5.76 (s, NH), 5.65 (s, NH), 5.04 (s, NH), 
3.53 (s, 16H), 3.26 (s, 24H), 1.55 (s, 12H), 1.36 (s, 72H).13C NMR (75.5 MHz, CDCl3) 
δ:  165.73, 165.51, 165.32, 156.12, 79.02, 78.78, 78.76, 47.35, 46.63, 46.57, 46.42, 
40.57, 40.42, 40.35, 38.38, 38.21, 38.12, 28.30.  MALDI-MS (m/z):  calcd 1678.0285, 
found 1679.9914 [M+H]+, 1700.9791 [M+Na]+, 1716.9474 [M+K]+. 
Compound 7-N.  2 (47 mg, 0.23 mmol) and Hünig’s Base (0.05 mL, 0.29 mmol) 
was added to a solution of 6-N (145 mg, 0.08 mmol) in 4 mL THF in a pressure flask.  
The reaction was stirred at 70 °C for 48 hours, and upon cooling, the solution was 
filtered.  The filtrate was then rotovapped, dissolved in DCM, extracted with water (3 x 
50 mL), dried over magnesium sulfate, and rotovapped.  The product was then purified 
using silica gel column chromatography with a 19:1 (DCM: MeOH) to 9:1:1% 
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(DCM:MeOH:NH4OH) gradient.  Yield:  50 mg (32%).  1H NMR (300 MHz, CDCl3) δ:  
6.26 (s, NH), 5.62 (s, NH), 3.54-3.26 (br, 56H), 2.91 (s, NH), 1.39 (m, 99H).  13C NMR 
(75.5 MHz, CDCl3) δ:  165.68, 165.62, 165.58, 165.52, 156.39, 156.25, 156.20, 156.17, 
156.12, 156.09, 79.06, 79.03, 78.92, 78.91, 78.83, 47.64, 47.59, 47.44, 47.35, 47.32, 
47.22, 47.03, 47.01, 39.87, 39.79, 39.74, 39.67, 39.65, 28.43, 28.32.  MALDI-MS (m/z):  
cacld 2047.3106, found 2049.4480 [M+H]+, 2061.4207 [M+Na]+ , 2071.4383 [M + K]+. 
Compound 7-O.   Oxy-ethylene diamine (0.04 mL, 0.39 mmol) and Hünig’s 
Base (0.07 mL, 0.40 mmol) was added to a solution of 6-O (221 mg, 1.3 mmol) in 1.3 
mL THF in a pressure flask.  The reaction was stirred at 70 °C for 48 hours, and upon 
cooling, the solution was filtered.  The filtrate was then rotovapped, dissolved in DCM, 
extracted with water (3 x 50 mL), dried over magnesium sulfate, and rotovapped.  The 
product was then purified using silica gel column chromatography with a 19:1 (DCM: 
MeOH) to 9:1:1% (DCM:MeOH:NH4OH) gradient.  Yield:  139 mg (61%).  1H NMR 
(300 MHz, CDCl3) δ:  5.71 (s, br, NH), 3.58 (s, 38H), 3.30 (s, 16H),  2.71 (s, NH), 2.08 
(s, 2H), 1.41 (s, 72H).  13C NMR (75.5 MHz, CDCl3) δ:  165.46, 156.15, 78.86, 69.76, 
47.33, 46.58, 40.88, 40.34, 40.21, 38.20, 28.35, 28.30.  MALDI-MS (m/z):  cacld 
1750.1054, found 1751.1823 [M+H]+, 1774.1702 [M+Na]+.  
Compound 7-C.  Pentane diamine (0.03 mL, 0.27 mmol) and Hünig’s Base (0.05 
mL, 0.27 mmol) was added to a solution of 6-C (153 mg, 0.09 mmol) in 1 mL THF in a 
pressure flask.  The reaction was stirred at 70 °C for 48 hours, and upon cooling, the 
solution was filtered.  The filtrate was then rotovapped, dissolved in DCM, extracted 
with water (3 x 50 mL), dried over magnesium sulfate, and rotovapped.  The product 
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was then purified using silica gel column chromatography with a 19:1 (DCM: MeOH) to 
9:1:1% (DCM:MeOH:NH4OH) gradient.  Yield:  97 mg (61%).  1H NMR (300 MHz, 
CDCl3) δ:  5.96 (s, NH), 5.83 (s, NH), 5.71 (s, NH), 5.26 (s, NH), 4.83 (s, NH), 3.52 (s, 
16H), 3.26 (s, 24H), 2.95 (s, 2H), 1.71 (s, 2H), 1.51 (s, 12H), 1.36 (m, 72H), 1.18 (m, 
6H).  13C NMR (75.5 MHz, CDCl3) δ:  165.32, 156.25, 79.07, 47.44, 46.63, 40.50, 
38.23, 29.63, 29.19, 28.43, 28.37, 26.89, 24.23.  MALDI-MS (m/z):  cacld 1744.1676, 
found 1745.0729 [M+H]+, 1768.0572 [M+Na]+ , 1784.0320 [M + K]+. 
pH Responsive Dendrimer Synthesis and Characterization.   
Compound 8.  Diethanolamine (21.23 mL, 221.5 mmol) was dissolved in 40 mL 
of acetone and placed in an ice bath.  A solution of cyanuric chloride (10.21 g, 55.4 
mmol) in 25 mL of acetone was added dropwise.  The reaction mixture was allowed to 
gradually warm to room temperature while stirring for 18 h.  The solution was then 
rotovapped and distilled water (90 mL) was added forming a slurry which was stirred at 
room temperature for 3 h before placing in ice bath to precipitate product.  The white 
powder was filtered and dried.  Yield:  16.32 g (92%).  1H NMR (300 MHz, DMSO-d6) 
δ:  4.77 (m, 4H), 3.58 (s, 16H). 13C NMR (75.5 MHz, DMSO-d6) δ:  168.16, 164.11, 
58.56, 50.81, 50.36, 39.50.  APCI-MS (m/z):  cacld 321.1204, found  322.1 [M+H]+. 
Compound 9.  Acetic anhydride (2.9 mL, 31.0 mmol) in 5 mL of DCM and 
acetyl chloride (2.2 mL, 31.0 mmol) in 5 mL of DCM is added dropwise to a slurry of 8 
(985 mg, 3.1 mmol) in 15 mL of DCM.  The reaction is then allowed to stir for 18 h 
obtaining a clear solution.  Triethylamine (1.5 mL, 10.8 mmol) is added, and then the 
mixture is slowly added to a solution of saturated sodium bicarbonate and stirred until 
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the evolution of gas is no longer apparent.  The organic layer is washed with saturated 
sodium bicarbonate (3 x 150 mL), dried with magnesium sulfate, filtered, and 
rotovapped.  The product is further purified by silica gel column chromatography using 
10:1 (CHCl3:EtOAc) as the eluent.  Yield:  1.39 g (92%)  1H NMR (300 MHz, CDCl3) δ:  
4.26 (t, J=5.50, 8H), 3.81 (m, 8H), 2.04 (d, J=3.30, 12H).  13C NMR (75.5 MHz, CDCl3) 
δ:  170.084, 164.88, 99.85, 62.38, 61.64, 47.38, 47.24, 20.89, 20.84.  ESI-MS (m/z):  
cacld 489.1626, found 490.1674 [M+H]+, 512.1548 [M+Na]+. 
Compound 10.  9 (660 mg, 1.4 mmol) is dissolved in 15 mL of THF and placed 
in a dry-ice/isopropyl alcohol bath.  N-aminoethylpiperazine (0.71 mL, 5.4 mmol) is 
added dropwise and the reaction is allowed to warm to room temperature while stirring 
for approximately 18 h. The reaction mixture is rotovapped and purified by silica gel 
column chromatography using a 19:1—9:1 (DCM:MeOH) gradient.  Yield:  656 mg 
(84%).  1H NMR (300 MHz, CDCl3) δ:  4.24 (d, J=4.95, 8H), 3.76 (m, 12H), 2.84 (d, 
J=4.40, 2H), 2.43 (s, 8H), 2.03 (d, J=4.40, 12H).  13C NMR (75.5 MHz, CDCl3) δ:  
170.97, 165.11, 99.83, 62.63, 60.39, 53.12, 46.96, 42.98, 38.41, 20.95.  ESI-MS (m/z):  
cacld 582.3126, found 583.3261 [M+H]+. 
Compound 11.  Cyanuric Chloride (87.0 mg, 0.47 mmol) is dissolved in 10 mL 
of THF and placed in an ice bath.  DIPEA (0.24 mL, 1.4 mmol) and 10 (656 mg, 1.1 
mmol) is added and the reactions is allowed to slowly come to room temperature while 
stirring for 18 h.  The solution is then rotovapped and purified by silica gel column 
chromatography using 1:1:3% (CHCl3:EtOAc:MeOH) as the eluent.  Yield:  184 mg 
(31%).  1H NMR (300 MHz, CDCl3) δ:  6.05 (s, NH), 4.22 (t, J=5.64, 16H), 3.75-3.68 
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(m, 24H), 3.49 (d, br, 4H), 2.53 (d, br, 4H), 2.43 (s, 8H), 2.01 (s, 24H).  13C NMR (75.5 
MHz, CDCl3) δ:  170.87, 165.40, 165.07, 164.63, 99.79, 62.57, 62.47, 56.27, 52.70, 
46.91, 42.83, 37.25, 20.93. MALDI-MS (m/z):  cacld 1275.5875, found 1276.6317 
[M+H]+. 
Compound 12.  A solution of N-aminoethylpiperazine (0.5 mL, 3.8 mmol) in 8 
mL of DCM (0.5 M) was placed in an ice bath, and a solution of ethyl trifluoroacetate 
(0.5 mL, 4.2 mmol) in 2 mL DCM (2M) was added dropwise.  The solution was stirred 
at 0 °C for 30 min. then further allowed to stir for an hour at room temperature.  At this 
time, a solution of triethylamine (0.6 mL, 4.3 mmol) and di-tert-butyl dicarbonate (954 
g, 4.2 mmol) in 2 mL DCM (2 M) was added dropwise.  The reaction was allowed to stir 
at room temperature for 18 hours.  Then, the reaction mixture was extracted with 
saturated sodium bicarbonate (2 x 100 mL), dried over magnesium sulfate, and 
rotovapped.  Ethanol (19 mL) and 3M NaOH (15 mL) was added to the residue and the 
mixture was allowed to stir at room temperature for 6 h.  At this time, the solution was 
rotovapped, dissolved in DCM, extracted with saturated NaCl (3 x 50 mL), dried over 
magnesium sulfate, filtered, and rotovapped.  Yield:  692 mg (79%).   1H NMR (300 
MHz, CDCl3) δ:  3.39 (m, 4H), 2.79 (t, J=5.91, 2H), 2.40 (m, 8H), 1.42 (s, 9H).  13C 
NMR (75.5 MHz, CDCl3) δ:  154.68, 79.57, 60.18, 52.93, 43.73, 43.24, 38.27, 28.35.  
ESI-MS (m/z):  cacld 229.1790, found 230.1813 [M+H]+. 
Compound 13.  Cyanuric chloride (226 mg, 1.2 mmol) was dissolved in 12 mL 
THF and 12 (1.94 g), 8.5 mmol) was added.  The solution was heated to 70 °C and 
allowed to react for 1 week.  The solution was then filtered, rotovapped, and purified 
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using silica gel column chromatography with a DCM—1:1:1% (DCM:EtOAc:MeOH) 
gradient.  Yield:  126 mg (43%).  1H NMR (300 MHz, CDCl3) δ:  5.34 (s, NH), 3.41 (s, 
18H), 2.51 (s, 6H), 2.39 (s, 12H), 1.44 (s, 27H).  13C NMR (75.5 MHz, CDCl3) δ:  
168.08, 156.77, 154.66, 79.61, 69.24, 56.95, 52.93, 52.84, 52.66, 43.89, 43.60, 43.11, 
37.05, 28.45, 28.37.   ESI-MS (m/z):  cacld 762.5228, found 763.5485 [M+H]+. 
  Compound 14.  13 (107 mg, 0.14 mmol) is dissolved in DCM (2mL) and 
trifluoroacetic acid (2 mL) is added.  The reaction is allowed to stir for 24 h at room 
temperature, rotovapped, and DIPEA is added (5 mL, 26 mmol). 
‘Divergent Diversity’ Dendrimer Synthesis and Characterization. 
Compound 15.  Cyanuric chloride (1.04 g, 5.6 mmol), 1-Boc-piperazine (3.69 g, 
19.8 mmol), and DIPEA (9.8 mL, 56.4 mmol) were dissolved in THF (56 mL) and 
placed in a pressure flask.  The mixture was heated to 70° C and allowed to stir for 48 h.  
The solution was rotovapped, dissolved in DCM (50 mL), extracted with water (3 x 125 
mL), dried over magnesium sulfater, filtered, and rotovapped.  The residue was 
dissolved in a minimal amount of DCM, excess MeOH was added, and the solution 
rotovapped until it became slightly cloudy.  More DCM was added and it was again 
rotovapped until the solution became slightly cloudy.  At this time the flask was placed 
in the freezer to reprecipitate the product.  The next day, the precipitate was filtered and 
dried.  Yield:  2.98 g  (83%).  1H NMR (300 MHz, CDCl3) δ:  3.72 (m, 12H), 3.42 (m, 
12H), 1.46 (s, 27H).  13C NMR (75.5 MHz, CDCl3) δ:  164.68, 155.97, 79.30, 44.94, 
37.32, 28.36, 27.69.   ESI-MS (m/z):  cacld 633.3962, found 634.4021 [M+H]+. 
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Compound 16.  15 (1.55 g, 2.45 mmol) was dissolved in DCM (22 mL) and 
trifluoroacetic acid (22 mL) was added.  The reaction was allowed to stir for 4 h at room 
temperature.  The solution was then rotovapped repeatedly, rinsing well with DCM each 
time.  1M NaOH (35 mL) was added to the residue until a pH 14 was reached and then 
the solution was extracted with CHCl3 (3 x 200 mL), or until UV activity was no longer 
detected in the aqueous layer.  The combined portions were dried over magnesium 
sulfate, filtered, and rotovapped.  Yield:  779 mg (95%).  1H NMR (300 MHz, CDCl3) δ:  
3.69 (m, 12H), 2.82 (m, 12H), 1.85 (s, NH).  13C NMR (75.5 MHz, CDCl3) δ:  165.24, 
45.96, 44.19.   ESI-MS (m/z):  cacld 333.2398, found 334.2334 [M+H]+. 
Compound 17.  Cyanuric chloride (2.0 g, 10.8 mmol) was dissolved in acetone 
(43 mL) to obtain a 0.25 M solution.  1-Boc-piperazine (1.8 g, 9.7 mmol) was dissolved 
in acetone (16 mL) and sodium bicarbonate (940 mg, 11.2 mmol) dissolved in water (18 
mL) to obtain 0.6 M solutions of each.  The three solutions were chilled, and water (65 
mL) was placed in an ice bath to cool, also.  A slurry of cyanuric chloride (0.1 M) was 
then made by adding the cyanuric chloride solution to the well stirred ice water.  Then 
the cold solutions of Boc-piperazine and NaHCO3 were added, and the reaction was 
allowed to stir at 0 °C for 2 h.  Precipitation of the product occurs, and after the 2 h the 
reaction mixture is filtered.  The precipitate is washed with cold water and dissolved in 
DCM (150 mL).  The solution is extracted with water (150 mL), dried over magnesium 
sulfate, filtered, rotovapped, and dried.  The product was then purified using silica gel 
column chromatography with 20:1 (CHCl3:EtOAc) as the eluent.  Yield:  3.07 g (95%).  
1H NMR (300 MHz, CDCl3) δ:  3.84 (m, 4H), 3.49 (m, 4H), 1.46 (s, 9H).  13C NMR 
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(75.5 MHz, CDCl3) δ:  170.39, 154.34, 80.63, 43.93, 28.31.  ESI-MS (m/z):  cacld 
333.0759, found 334.0781 [M+H]+. 
Compound 18.  Bis(3-aminopropyl)amine (1.62 mL, 11.3 mmol) and DIPEA (6.0 
mL, 34.0 mmol) were dissolved in THF (25 mL), and BOC-ON (5.58 g, 22.7 mmol) was 
dissolved in THF (25 mL).  Both solutions were cooled to 0 °C and then combined.  The 
mixture was allowed to gradually warm to room temperature and stirred for 4 h.  The 
solution was then rotovapped, dissolved in DCM (100 mL), extracted with 5% NaOH (3 
x 100 mL), dried over magnesium sulfate, filtered, and rotovapped again.  The residue 
was then reprecipitated from DCM with petroleum ether overnight in the freezer.  The 
precipitate is then filtered and dried.  Yield:  2.97 g (79%).  1H NMR (300 MHz, CDCl3) 
δ:  5.20 (s, NH), 3.18 (q, J=6.05, 4H), 2.62 (t, J=6.46, 4H), 1.62 (qd, J=6.33, 6.51, 4H), 
1.41 (s, 18H).  13C NMR (75.5 MHz, CDCl3) δ:  156.08, 78.95, 47.41, 38.92, 29.73, 
28.40.   ESI-MS (m/z):  cacld 331.2471, found 332.2563 [M+H]+. 
Compound 19.  Cyanuric chloride (2.04 g, 11.4 mmol) was dissolved in acetone 
(45 mL) to obtain a 0.25 M solution.  18 (3.4 g, 10.2 mmol) was dissolved in acetone (17 
mL) and sodium bicarbonate (984 mg, 11.4 mmol) dissolved in water (19 mL) to obtain 
0.6 M solutions of each.  The three solutions were chilled, and water (69 mL) was placed 
in an ice bath to cool, also.  A slurry of cyanuric chloride (0.1 M) was then made by 
adding the cyanuric chloride solution to the well stirred ice water.  Then the cold 
solutions of 18 and NaHCO3 were added, and the reaction was allowed to stir at 0 °C for 
2 h.  Precipitation of the product occurs, and after the 2 h the reaction mixture is filtered.  
The precipitate is washed with cold water and dissolved in DCM (150 mL).  The 
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solution is extracted with water (150 mL), dried over magnesium sulfate, filtered, 
rotovapped, and dried.  Yield:  4.35 g (89%).  1H NMR (300 MHz, CDCl3) δ:  5.04 (s, 
NH), 3.61 (t, J=6.88, 4H), 3.11 (q, J=6.14, 4H), 1.78 (m, J=6.67, 4H), 1.43 (s, 18H).  13C 
NMR (75.5 MHz, CDCl3) δ:  170.08, 164.66, 155.97, 79.29, 44.93, 37.31, 28.35, 27.67.  
ESI-MS (m/z):  cacld 478.1862, found 479.1988 [M+H]+, 501.1783 [M+Na]+. 
Compound 20.  19 (1.60 g, 3.3 mmol), DIPEA (1.74 mL, 10 mmol), and 
propargylamine (0.23 mL, 3.3 mmol) were dissolved in THF (40 mL) and allowed to stir 
at room temperature for 18 h.  The solution was rotovapped, dissolved in DCM (100 
mL), extracted with water (3 x 100 mL) and brine (1 x 100 mL), dried over magnesium 
sulfater, filtered, and rotovapped.  The compound was then purified using silica gel 
column chromatography with 8:1 (CHCl3:EtOAc) as the eluent.  Yield:  1.34g (81%).  
1H NMR (300 MHz, CDCl3) δ:  6.29 (s, NH), 5.54 (s, NH), 4.93 (s, NH), 4.18 (m, 2H), 
3.58 (m, 4H), 3.10 (m, 4H), 2.22 (s, 1H), 1.76 (m, 4H), 1.44 (m, 18H).  13C NMR (75.5 
MHz, CDCl3) δ:  167.71, 165.02, 164.86, 156.11, 155.89, 79.66, 78.91, 71.39, 44.28, 
43.70, 43.67, 37.63, 36.79, 30.77, 28.41, 27.89, 27.69.  ESI-MS (m/z):  cacld 497.2517, 
found 498.2634 [M+H]+. 
Compound 21.  16 (490 mg, 1.5 mmol) was dissolved in THF (50 mL), and 17 
(1.53 g, 4.6 mmol) was separately dissolved in THF (50 mL) to give a slurry.  The 
solutions were cooled to 0 °C and DIPEA (2.6 mL, 14.7 mmol) was added to the 
solution of 16.  The two solutions were then combined and stirred at 0 °C for 1 h then 
allowed to warm to room temperature and stir for 18 h.  The reaction mixture was then 
rotovapped, dissolved in DCM (100 mL), extracted with water (3 x 100 mL), dried over 
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magnesium sulfater, filtered, and rotovapped.  The compound was purified using silica 
gel chromatography with a 8:1—4:1 (DCM:EtOAc) gradient.  Yield:  1.59 g (88%).  1H 
NMR (300 MHz, CDCl3) δ:  3.81 (s, br, 36H), 3.45 (s, br, 12H), 1.47 (s, 27H).  13C 
NMR (75.5 MHz, CDCl3) δ:  169.65, 167.31, 164.42, 154.59, 80.24, 43.29, 43.23, 43.01, 
42.95, 42.88, 42.79, 42.74, 28.35.  MALDI-MS (m/z):  cacld 1224.5367, found 
1225.5638 [M+H]+, 1248.5532 [M+Na]+, 1263.5167 [M+K]+. 
Compound 22.  21 (514 mg, 0.42 mmol), DIPEA (0.44 mL, 2.5 mmol), and 2-(2-
aminoethoxy)ethanol (0.25 mL, 2.5 mmol) were dissolved in THF (4 mL) and placed in 
a pressure flask.  The mixture was heated to 70 °C and allowed to stir for 24 h.  The 
reaction mixture was then rotovapped, dissolved in DCM (50 mL), extracted with water 
(3 x 75 mL), dried over magnesium sulfater, filtered, and rotovapped.  The product was 
then purified using silica gel column chromatography with 25:1 (DCM:MeOH) as the 
eluent.  Yield:  385 mg (64%).  1H NMR (300 MHz, CDCl3) δ:  5.40 (s, NH), 3.73 (m, 
36H), 3.59 (m, 18H), 3.41 (s, br, 12H), 1.46 (s, 27H).  13C NMR (75.5 MHz, CDCl3) δ:  
166.18, 165.28, 165.04, 154.76, 79.89, 72.33, 70.11, 61.63, 42.97, 42.89, 40.46, 28.38.  
MALDI-MS (m/z):  cacld 1431.8436, found 1432.8631 [M+H]+, 1454.8362 [M+Na]+, 
1470.8266 [M+K]+. 
Compound 23.  Concentrated HCl was added to a slurry of 22 in MeOH.  The 
solution became clear and was allowed to stir at room temperature for 18 h.  The 
solution was then rotovapped until only about 5 mL of water remained, and the residue 
was diluted with distilled water (20 mL).  The solution was then extracted with DCM (3 
x 25 mL).  The aqueous layer was rotovapped and dried to form a white powder.  Yield:  
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83.4 mg (99%).  1H NMR (300 MHz, D2O) δ:  4.14 (br, 12H), 3.95 (br, 24H), 3.69 (br, 
18H), 3.64 (br, 6H), 3.34 (br, 12H).  13C NMR (75.5 MHz, D2O) δ:  161.9, 158.1, 156.0, 
154.3, 71.7, 68.6, 60.5, 43.5, 43.1, 40.7, 40.3.   MALDI-MS (m/z):  cacld 1131.6863, 
found 1132.8087 [M+H]+, 1170.7723 [M+K]+. 
Compound 24.  23 (83.4 mg, 0.06 mmol), DIPEA (0.2 mL, 1.1 mmol), and 20 
(194 mg, 0.39 mmol) were dissolved in THF (4 mL) and placed in a pressure flask.  The 
reaction is heated at 70 °C for 5 days at which time the mixture is rotovapped, dissolved 
in DCM, and extracted with water/saturated NaCl (3 x 75 mL).  The organic phase is 
dried with magnesium sulfate, filtered, and rotovapped.  Purification was attempted 
using silica gel column chromatography using a 19:1:10% (DCM:MeOH:EtOAc)—4:1 
(DCM:MeOH) gradient.  No appreciable amount of pure dendrimer was obtained.  
Presence of the dendrimer was confirmed by MALDI-MS; however, each fraction 
analyzed contained an impurity of unknown origin.  MALDI-MS (m/z):  cacld 
2515.5115, found 2517.4269 [M+H]+, 2539.3878 [M+Na]+. 
Iodinated Dendrimer Synthesis and Characterization. 
Compound 25.  16 (268 mg, 0.81 mmol) was dissolved in THF (20 mL) and 
placed in an ice bath to cool.  DIPEA (1.4 mL, 8.1 mmol) and then 19 (1.24 g, 2.58 
mmol) was added, and the reaction was allowed to slowly warm to room temperature 
and stir for 18 h.  The solution was rotovapped, dissolved in CHCl3 (100 mL), extracted 
with water (3 x 100 mL), dried over magnesium sulfate, filtered, and rotovapped.  The 
compound was then purified using silica gel column chromatography with 4:1 
(DCM:EtOAc) as the eluent.  Yield:  1.07 g (80%).  1H NMR (300 MHz, CDCl3) δ:  
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5.59 (s, NH), 4.84 (s, NH), 3.85 (s, 24H), 3.56 (m, 12H), 3.08 (m, 12H), 1.75 (m, 12H), 
1.43 (s, 54H).  13C NMR (75.5 MHz, CDCl3) δ:  169.24, 165.15, 164.91, 164.25, 156.12, 
155.81, 79.24, 78.80, 43.81, 43.36, 43.29, 42.83, 42.59, 37.70, 36.72, 28.38, 28.35, 
27.82, 27.74.   MALDI-MS (m/z):  cacld 1659.8675, found 1660.1431 [M+H]+, 
1682.1252 [M+Na]+. 
Compound 26.  25 (685 mg, 0.41 mmol) was dissolved in THF (10 mL) and 
excess piperidine (0.4 mL, 4.1 mmol) was added.  The mixture was allowed to stir at 
room temperature for 18 h.  Then, the solution was filtered through a silica plug, rinsing 
well with THF (150 mL) to remove most of the piperidine.  The solution was then 
rotovapped, dissolved in DCM (50 mL), extracted with water (3 x 75 mL), dried over 
sodium sulfate, and filtered through a second silica plug rinsing with 19:1 
(DCM:MeOH) (400 mL).  Yield:  737 mg (99%).  1H NMR (300 MHz, CDCl3) δ:  5.29 
(s, NH), 3.80 (s, br, 24H), 3.72 (s, br, 12H), 3.59 (s, br, 12H), 3.06 (s, br, 12H), 1.70 (m, 
br, 12H), 1.59 (m, br, 18H), 1.41 (s, 54H).  13C NMR (75.5 MHz, CDCl3) δ:  165.87, 
165.25, 164.80, 155.97, 78.93, 44.10, 43.15, 42.97, 41.52, 37.10, 36.24, 28.49, 27.59, 
25.76, 24.88.   MALDI-MS (m/z):  cacld 1807.2050, found 1808.6305 [M+H]+, 
1829.5946 [M+Na]+. 
Compound 27.  26 (634 mg, 0.35 mmol) was placed in MeOH (8mL) to form a 
cloudy solution and concentrated HCl (4 mL) was added.  The solution became clear and 
the mixture was allowed to stir at room temperature for 18 h.  For isolation of the amine-
HCl salt, the solution was then rotovapped, adding ethanol to help remove water.  
(Alternatively, the neutral compound may be isolated by adding 3M NaOH until pH 14 
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is reached and extracting with CHCl3 until no UV activity is detected in the aqueous 
layer.)  Yield:  536 mg (>99%)  1H NMR (300 MHz, CDCl3) δ:  3.78 (s, 24H), 3.70 (s, 
12H), 3.62 (t, J=6.60, 12H), 2.67 (t, J=5.91, 12H), 1.71 (m, 12H), 1.61 (m, 6H), 1.53 (s, 
br, 12H).  13C NMR (75.5 MHz, CDCl3) δ:  165.67, 165.39, 164.93, 44.12, 43.11, 42.63, 
39.21, 39.17, 31.46, 25.83, 25.02.   MALDI-MS (m/z):  cacld 1206.8904, found 
1207.7268 [M+H]+. 
Compound 28.  27 (282 mg, 0.23 mmol) was dissolved in H2O (2 mL).  DIPEA 
(0.69 mL, 4.0 mmol) and EtOAc (3 mL) was added.  19 (960 mg, 2.0 mmol) was 
dissolved in DCM (9 mL) and added to the solution.  The mixture was allowed to stir at 
room temperature for about 1 h.  The solution was then rotovapped, and the residue was 
dissolved in DCM (50 mL).  This solution was extracted with water (3 x 75 mL), dried 
over magnesium sulfate, filtered, and purified by silica gel column chromatography 
using 4:1:1% (DCM: EtOAc:MeOH).  Yield:  541 mg (60%).  1H NMR (300 MHz, 
CDCl3) δ:  5.67-5.60 (br, NH), 4.99 (s, br, NH), 3.81 (s, br, 24H), 3.74 (s, br, 12H), 3.63-
3.55 (br, 36H), 3.38 (s, br, 12H), 3.06 (s, 24H), 1.84-1.55 (br, 72H), 1.42-1.40 (d, br, 
108H).  13C NMR (75.5 MHz, CDCl3) δ:  165.31, 165.29, 165.05, 164.81, 156.10, 
155.83, 79.05, 78.73, 44.24, 44.04, 43.37. 43.25, 43.07, 37.79, 37.43, 36.73, 27.86, 
25.77. 24.88.   MALDI-MS (m/z):  cacld 3860.1476, found 3865.1311 [M+H]+, 
3887.0812 [M+Na]+, 3903.0288 [M+K]+. 
 Compound 29.  28 (203 mg, 0.05 mmol) was dissolved in THF (10 mL) and 
excess piperidine (0.1 mL, 1.0 mmol) was added.  The mixture was allowed to stir at 
room temperature for 18 h.  The solution was filtered through a silica gel plug rinsing 
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with THF (125 mL), rotovapped, dissolved in DCM (25 mL), extracted with water (3 x 
50 mL), dried over sodium sulfate, filtered, and rotovapped.  Yield:  215 mg (98%).  1H 
NMR (300 MHz, CDCl3) δ:  5.25 (s, NH), 3.79 (s, br, 24H), 3.68 (s, br, 36H), 3.53 (s, 
br, 36H), 3.34 (s, 12H), 3.02 (s, 24H), 1.81 (s, 12H), 1.66-1.54 (m, br, 78H), 1.39 (s, 
108H).  13C NMR (75.5 MHz, CDCl3) δ:  165.83, 165.34, 164.93, 164.76, 155.96, 78.79, 
44.08, 43.07, 42.09, 41.81, 37.08, 28.55, 28.28, 27.66, 25.75, 24.99.  MALDI-MS (m/z):  
cacld 4154.8224, found 4157.1251 [M+H]+, 4179.9701[M+Na]+. 
Compound 30.  29 (137 mg, 0.03 mmol) was placed in MeOH (2 mL) to form a 
cloudy solution and concentrated HCl (1 mL) was added.  The solution became clear and 
the mixture was allowed to stir at room temperature for 18 h.  For isolation of the amine-
HCl salt, the solution was then rotovapped, adding ethanol to help remove water.  Yield:  
113 mg (>99%).  1H NMR (300 MHz, CDCl3) δ:  3.80 (s, 24H), 3.72-3..56 (br, 72H), 
3.32 (s, 12H), 2.64 (s, 12H), 2.26 (s, 24H), 1.80-1.50 (br, 78H).  13C NMR (75.5 MHz, 
CDCl3) δ:  167.83, 165.95, 165.34, 165.15, 164.74, 43.94, 43.80, 43.79, 43.76, 42.94, 
42.90, 42.87, 38.88, 31.19, 25.57, 24.76.   MALDI-MS (m/z):  cacld 2954.1932, found  
2955.1557 [M+H]+. 
Compound 31.  Cyanuric chloride (278 mg, 1.5 mmol) and 2,4-diiodoaniline 
(1.04 g, 3.0 mmol) were dissolved in THF (15 mL) and allowed to stir at room 
temperature for 1 h.  The reaction mixture was then filtered to remove precipitated salts.  
The filtrate was rotovapped, dissolved in CHCl3 (25 mL), extracted with 0.05 M HCl (2 
x 50 mL) and brine (1 x 50 mL), dried with sodium sulfate, filtered, and rotovapped until 
a minimal amount of CHCl3 remained.  At this time, hexanes was added and the flask 
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was placed in the freezer.  The next day the precipitate was isolated by filtration and 
dried.  Yield:  633 mg (85%).  1H NMR (300 MHz, Acetone-d6) δ:  9.65 (s, NH), 8.32 
(d, J=1.93, 1H), 7.86 (d, J=1.93) and 7.84 (d, J=1.93) 1H, 7.41 (s) and 7.38 (s) 1H.  13C 
NMR (75.5 MHz, Acetone-d6) δ:  166.44, 165.22, 147.73, 139.13, 130.44, 98.90, 93.29. 
Compound 32.  Excess piperazine (240 mg, 2.8 mmol) was dissolved in DCM 
(20 mL) and placed in an ice bath under a nitrogen atmosphere.  NHS-m-d-PEG with 
molecular weight of 1214 Da (518 mg, 0.43 mmol) was dissolved in DCM (15 mL) and 
quickly added to the piperazine solution.  The reaction was allowed to stir under 
nitrogen, slowly warm to room temperature, and stir for 18 h at room temperature.  The 
solution was then rotovapped and purified using silica gel column chromatography with 
9:1:1% (DCM:MeOH:NH4OH) as the eluent.  Yield:  492 mg (98%).  1H NMR (300 
MHz, CDCl3) δ:  3.61 (m, br, 97H), 3.35 (s, 2H), 2.60 (t, J=6.88, 4H), 2.46 (s, br, 4H). 
13C NMR (75.5 MHz, CDCl3) δ:  71.84, 70.58, 70.47, 70.34, 58.96, 33.48.  MALDI-MS 
(m/z):  cacld 1185.44, found 1185.2719 [M+H]+, 1207.2245 [M+Na]+, 1223.1993 
[M+K]+. 
Compound 33.  Excess piperazine (212 mg, 2.4 mmol) was dissolved in DCM 
(20 mL) and placed in an ice bath under a nitrogen atmosphere.  mPEG-SPA-2000 with 
molecular weight of approximately 2000 Da (700 mg, 0.35 mmol) was dissolved in 
DCM (15 mL) and quickly added to the piperazine solution.  The reaction was allowed 
to stir under nitrogen, slowly warm to room temperature, and stir for 18 h at room 
temperature.  The solution was then rotovapped and purified using silica gel column 
chromatography with 9:1:1% (DCM:MeOH:NH4OH) as the eluent.  Yield:  607 mg 
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(88%).  1H NMR (300 MHz, CDCl3) δ:  3.57 (m, br, 169H), 3.31 (s, 2H), 3.08 (br, 2H), 
2.97 (br, 2H), 2.56 (t, J=6.19, 4H). 13C NMR (75.5 MHz, CDCl3) δ:  71.72, 70.55, 70.39, 
70.35, 70.31, 70.21, 70.07, 67.72, 58.86.  MALDI-MS (m/z):  cacld 1966.35, found 
2286.7140 (median of mass range from 1670.6244-2852.7119). 
Compound 34.  30 (177 mg, 0.056 mmol) was placed in DCM (10 mL) and 
MeOH (1 mL) to obtain a slurry.  DIPEA (15.3 mL, 3.4 mmol) and 31 (531 mg, 1.1 
mmol) were added.  The solution was allowed to stir at room temperature for 48 h.  The 
solution was then rotovapped, dissolved in CHCl3 (80 mL), extracted with water (3 x 
150 mL), dried over sodium sulfate, filtered, and rotovapped.  The compound was 
purified using silica gel column chromatography using 100:1 (CHCl3:MeOH) as the 
eluent.  Yield:  396 mg (82%).   1H NMR (300 MHz, CDCl3) δ:  9.82 (s, NH), 8.03-7.19 
(br, 36H), 6.93 (br, NH), 6.53 (br, NH) 5.46 (br, NH), 3.77-3.26 (br, 132H), 1.93-1.40 
(br, 90H).  13C NMR (75.5 MHz, CDCl3) δ:  .   MALDI-MS (m/z):  cacld 8423.9560, 
found a series of peaks with differences of 125 or 127 indicating loss of iodine with a 
median of  8036.32.  Combustion elemental analysis (CHN/I):  theoretical C 35.46, H 
3.44, N 19.93, I 36.12; found C 35.26, H 3.42, N 18.94, I 35.61. 
Compound 35.  34 (48 mg, 0.006 mmol), 32 (119 mg, 0.1 mmol), and DIPEA 
(0.03 mL, 0.14 mmol) were dissolved in THF (2.9 mL) and placed in a pressure flask.  
The reaction mixture was heated to 70 °C for 3 days.  The solution was then rotovapped, 
dissolved in a minimal amount of deionized water, and filtered through a 0.2 μm syringe 
filter to remove any undissolved particles.  The solution was then placed into 10 kDa 
molecular weight cut-off dialysis membrane tubing, clamped on both ends, and placed 
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into a stirred 4 L container of deionized water for one week.  The water was removed 
and replaced 3 times a day for the first day, 2 times a day for days 2-5, and 1 time on 
days 6 and 7.   After ensuring removal of excess PEG was complete by HPLC-RI 
analysis, the sample was rotovapped and dried.  Yield:  79 mg (62%).  MALDI-MS 
(m/z):  cacld 22220.6, found:  series of peaks ranging from approximately 15-22 kDa 
with a median value of 18746.67. 
Compound 36.  34 (17.5 mg, 0.002 mmol), 33 (75 mg, 0.038 mmol), and DIPEA 
(0.01 mL, 0.057 mmol) were dissolved in THF (1 mL) and placed in a pressure flask.  
The reaction mixture was heated to 70 °C for 3 days.  The solution was then rotovapped, 
dissolved in a minimal amount of deionized water, and filtered through a 0.2 μm syringe 
filter to remove any undissolved particles.  The solution was then placed into 25 kDa 
molecular weight cut-off dialysis membrane tubing, clamped on both ends, and placed 
into a stirred 4 L container of deionized water for ten days.  The water was removed and 
replaced 3 times a day for the first day, 2 times a day for days 2-6, and 1 time on days 7-
10.  After ensuring removal of excess PEG was complete by HPLC-RI analysis, the 
sample was rotovapped and dried.  Yield:  57 mg (86%).  MALDI-MS (m/z):  cacld 
31727.0, found:  series of peaks ranging from approximately 30-36 kDa with a median 
value of 34639.44. 
Results and Discussion 
Isosteric Dendrimer Synthesis and Characterization.  The synthesis of a 
dendrimer based on melamine containing isosteric diamine linkers was attempted to 
investigate the effect of differing atom electronegativites on the encapsulation of 
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molecules such as drugs.  The convergent synthesis would yield a G2 dendrimer with 24 
primary amine groups which could then be further synthetically modified.  The synthesis 
proceeded through iterative reactions of cyanuric chloride with the diamine linkers.  For 
this study, the linkers chosen differed in the nature of the central atom.  Linkers of the 
form NH2(CH2)2X(CH2)2NH2 were utilized where X = N-Boc, O, or CH2 for  diethylene 
triamine, 2,2’-oxybis(ethylamine), and 1,5-diaminopentane, respectively.   
The synthesis of these dendrimers proved to be rather arduous with dimerizations 
and incomplete substitutions due to steric hinderence and reduced reaction rates causing 
low yields at each step.  Through a series of protections and deprotections, Boc 
protection of the secondary amine of diethylene triamine can be achieved in order to 
assure substitution of the primary amine onto the triazine ring using a method reported 
by Koščová, et al.181 (Scheme 18)  The amine derivative, the most interesting of the 
three, was carried through to near completion with only one step remaining.  Attempts to 
synthesize dendrimers with oxy and methylene derivatives were unsuccessful.  The final 
coupling step of the dendrimer synthesis proved to be quite difficult with many side 
products and incomplete substitutions. (Scheme 19) 
 
Scheme 18.  Synthesis of mono-Boc triamine linker.  a) CF3COOEt, DCM, 0 °C—RT 1.5 h, then (Boc)2O, 
Et3N, RT, 18 h.  b)NaOH, EtOH, RT, 18 h. 
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Scheme 19.  Synthesis of isosteric dendrimers.  c) CDI, Toluene, 65 °C, 3 h, then diethylene triamine, 65 
°C, 3 h.  d) C3N3Cl3, THF, DIPEA, 0 °C-RT, 18 h.  e) H2N(CH2)2X(CH2)2NH2, THF, DIPEA, 70 °C, 48 h. 
f) C3N3Cl3, THF, DIPEA, 0 °C-RT, 18 h.  g) H2N(CH2)2X(CH2)2NH2, THF, DIPEA, 70 °C, 48 h.  
h) C3N3Cl3, THF, DIPEA, 70 °C, 1 week. 
 
 
 
Upon completion of the synthesis, further studies would investigate the 
relationship of these differing atoms upon the noncovalent encapsulation of drug 
molecules into the interior of the dendrimer.  This would be a proof-of-concept 
experiment to demonstrate the best linker-type for encapsulation.  Presumably the most 
electronegative group, the amine, would demonstrate the greatest proficiency for 
noncovalent interactions with guest molecules followed by the oxy, and then the 
methylene group. 
A problem with the initial target dendrimer is the presence of amine groups on 
the periphery which are Boc-protected.  This leaves no selectivity for deprotection of 
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only the interior amines and would hinder any studies of drug encapsulation for fear of 
the exterior amines interfering with the interior amine interactions.  Changing the 
periphery groups to hydroxyls could remedy this, however the synthesis would still 
encounter similar problems of dimerization and incomplete substitutions, lowering 
yields and frustrating purification efforts. 
pH Responsive Dendrimer Synthesis and Characterization.  The synthesis of 
a G2 dendrimer containing nine additional protonation sites in the interior due to the 
incorporation of the linker aminoethyl piperazine was attempted.  The dendrimer would  
include 24 hydroxyl groups on the periphery which may be further synthetically 
modified to provide solubility, attach targeting moieties, etc.  The dendrimer would 
allow a study of how the electrostatic interactions between guest molecules and a 
melamine dendrimer would vary with pH, specifically an anionic guest such as the anti-
cancer drug methotrexate. 
The synthesis of this dendrimer, too, proved to be quite difficult presumably due 
to the extra effect of the basic tertiary amine incorporated with the linker.  The presence 
of the hydroxyl group along with the choice of linker made isolation of amine 
intermediates from impurities nearly impossible.  Acetylation of the hydroxyls solved 
this issue, but the incorporation of acetyl groups caused additional side products which 
were attributed to acetyl transfer. 
 A core comprised of three mono-Boc protected amino ethylpiperazines coupled 
to cyanuric chloride was synthesized with some degree of difficulty given that 
unexpected and unwanted side products were produced during the Boc protection of the 
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linker.  A G1 dendron was then to be coupled to the deprotected core in a hypercore type 
reaction as shown in Scheme 20.  No product was obtained, either due to sterics or 
absence of a strong enough exogenous base.  This method of dendrimer synthesis 
appeared to be of little utility. 
 
 
Scheme 20.  Incorporation of 3° amine linker to melamine dendrimer.  a) diethanolamine, acetone, 0 °C—
RT, 18 h.  b) acetic anhydride, acetyl chloride, DCM, RT, 18 h, then triethylamine.   
c) N-aminoethylpiperazine, THF, -50 °C—RT, 18 h.  d) C3N3Cl3, DIPEA, THF, 0 °C—RT, 18 h.  
e) CF3COOEt, DCM, 0 °C—RT 1.5 h, then (Boc)2O, Et3N, RT, 18 h.  f) C3N3Cl3, THF, 70 °C, 1 week.   
g) TFA/DCM 1:1, RT, 24 h.  h) THF, DPIEA, 70 °C, 3 days 
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 ‘Divergent Diversity’ Dendrimer Synthesis and Characterization.  Through 
the work of Dr. Emily Hollink, a ‘new’ route to synthesize melamine dendrimers was 
developed.  The dichlorotriazine method proceeds rapidly and requires less harsh 
conditions than the traditional routes employed in the Simanek group.  The method plays 
upon the differential reactivity of cyanuric chloride to afford monodisperse dendrimers 
divergently while still allowing for incorporation of various groups.53  Synthesis of the 
dichlorotriazine building blocks may be accomplished using green methods adopted 
from Lowe and co-workers.182  The reactions are performed in an acetone/water mixed 
solvent-system employing sodium bicarbonate as an exogenous base, and generally, 
precipitation of the product occurs allowing simple filtration of the product. 
Using this method a dendrimer was synthesized containing three reactive groups 
– hydroxyl, amine, and alkyne.  The G2 dendrimer would allow the attachment of drug 
molecules, fluorescent markers, and PEG chains for solubility and biocompatibility with 
three hydroxyl groups, three propargyl groups, and six amines. (Scheme 21) 
Problems with this synthesis occurred, however, when installing propargyl 
groups.  When treating a monochlorotriazine with propargyl amine, unwanted side 
products formed.  The propargyl amine must be appended as the second triazine 
substitution for the reaction to readily proceed.  However, this produces a situation in 
which attachment of a monochlorotriazine to the dendrimer must occur necessitating 
heating, long reaction times, and the use of a strong base to produce dendrimer in good 
yield.  The dendrimer was synthesized as shown by a crude mass spectrometry analysis, 
but purification afforded no appreciable amount of pure compound. 
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Scheme 21.  Synthetic strategy incorporating three functional groups.  a) DIPEA, THF, 70 °C, 48 h.  b) 
TFA/DCM (1:1), RT, 4 h.  c) NaHCO3, Acetone/Water, 0 °C, 2 h.  d) BOC-ON, DIPEA, THF, 0 °C—RT, 
4 h.  e) C3N3Cl3, NaHCO3, Acetone/Water, 0 °C, 2 h.  f) propargylamine, DIPEA, RT, 18 h.  g) DIPEA, 
THF, 0 °C—RT, 18 h.  h) aminoethoxyethanol, DIPEA, THF, 70 °C, 24 h.  i) HCl (conc.)/MeOH (2:1), 
RT, 18 h.  j) 20, DIPEA, THF, 70 °C, 5 days. 
 
 
 
Iodinated Dendrimer Synthesis and Characterization.  Melamine dendrimers 
have been synthesized as potential macromolecular CT imaging agents.  The synthesis 
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proceeded through a divergent pathway utilizing dichlorotriazine building blocks and 
commercially available 2,4-diiodoaniline.  The synthetic strategy was similar to that of 
the ‘divergent diversity’ dendrimer mentioned above.  Dendrimers are synthesized in 
good yield and with excellent purity using this method.  Formation of the G1-Cl is 
accomplished at room temperature.  The next step is what we refer to as “capping” in 
which the reactive chloride is barred from further reactive steps by treating with 
piperidine.  This reaction, too, is carried out under ambient conditions in good yield 
within 18 h.  The steps are then iterative to form the second generation. (Scheme 22)  
After deprotection, introduction of the iodine moiety occurs.   
A dichlorotriazine was synthesized with diiodoaniline.  To facilitate the reaction, 
two equivalents of diiodoaniline were necessary rather than using an exogenous base.  
Within one hour at room temperature, the dichlorotriazine was formed.  Filtration, 
followed by reprecipitation from dichloromethane with hexanes provided the desired 
dichlorotriazine in good yield.  Treating the G2-amine with the dichloro-diiodoaniline, 
again, at room temperature provided a dendrimer (34) with a molecular weight of 8423 
Da. (Scheme 23) 
This dendrimer (34) was shown to be monodisperse by multi-detector GPC 
analysis.  Taking into account that this technique will not give definitive data for 
dendrimers due to standardization with linear polystyrene, the evidence is fairly strong 
that dendrimers based on melamine synthesized by the dichlorotriazine route are 
monodisperse molecules.  The compound had a⎯Mn of 8,272 Da and a⎯Mw of 8,300 Da, 
which were in close agreement with the calculated molecular weight, and a 
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hydrodynamic radius of 1.757 nm.  The elemental analysis obtained for this compound 
was in fairly good agreement with expected calculated values.  Discrepancies can most 
likely be attributed to the encapsulation of solvent molecules such as hexanes.  MALDI 
mass spectrometry for this molecule shows peaks indicating ionized loss of iodine, 
making characterization by this method difficult. 
 
 
Scheme 22.  Divergent synthesis of precursor dendrimer.  a) DIPEA, THF, 0 °C—RT, 18 h.  b) piperidine, 
THF, RT, 18 h.  c) MeOH:HCl (conc.) (2:1), RT, 18 h.  d) 19, DIPEA, DCM/EtOAc/H2O, RT, 1 h.  e) 
piperidine, THF, RT, 1 h. 
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Scheme 23.  Synthesis of iodinated dendrimer.  g) 2,4-diiodoaniline, THF, RT, 1 h.  h) N2, DCM, 0 °C—
RT, 18 h.  i) DIPEA, DCM:MeOH (10:1), RT, 48 h.  j) DIPEA, THF, 70 °C, 3 days. 
 
 
 
Subsequent pegylation of the dendrimer 34 with PEG1000 or PEG2000 piperazine 
derivatives at 70 °C for 3 days yields G3 dendrimers with 24 iodine molecules and 
molecular weights of approximately 18 and 34 kDa, respectively, as determined by 
MALDI mass spectrometry. (Scheme 23)  Upon completion of dialysis using either 10 
kDa or 25 kDa molecular weight cut-off dialysis membranes, respectively, size 
exclusion chromatography/refractive index HPLC data was recorded to determine if any 
free PEG remained.  Each dendrimer showed a single peak for the desired product.   
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For the 34 kDa dendrimer, GPC data was also obtained.  The PDI was found to 
be 1.051 which was undoubtedly higher than the parent dendrimer due to the 
introduction of 12 PEG chains, each of which are not precisely monodisperse.  The 
molecular weight determination was in good agreement with mass spectral data.  The 
dendrimer had a⎯Mn of 34,618 Da and a⎯Mw of 36,367 Da and a hydrodynamic radius of 
4.281.  This synthesis affords pure material in good yields with only the PEGylation step 
requiring harsh reaction conditions or long reaction times.   
These dendrimers have an iodine content of approximately 17% and 9% by 
weight for (35) and (36), respectively.  The difference in iodine content paired with a 
difference in molecular weight would make for an interesting comparison during a CT 
scanning experiment.   If the dendrimers were compared to a commonly used, small 
molecule contrast agent such as Omnipaque, one would find that the dendrimers would 
have a longer retention time in the bloodstream allowing for longer evaluation times, 
increasing accuracy of diagnoses.  For the smaller of the two dendrimers with a higher 
iodine content compared to a larger molecular weight dendrimer with a lower iodine 
weight content, the results would be indicative of the importance of both of these factors 
combined. 
Conclusions 
 Dendrimers based on melamine have many potential applications in the drug 
delivery realm.  Whether it is noncovalent encapsulation or covalent attachment, these 
dendrimers are promising vehicles for anti-cancer treatment and macromolecular 
contrast agents, among other applications.  With the proper choice of linker, and a 
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synthetic route that limits harsh reactions conditions, prolonged reaction times, or 
laborious purification, the possibilities are limitless for incorporation of various groups 
of choice onto monodisperse molecules to fulfill the application at hand. 
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CHAPTER V 
CONCLUSION 
This work focused on organic synthesis using the 1,3,5-triazine moiety, 
specifically cyanuric chloride for the development of chemistry with practical 
applications for education, remediation, and drug delivery.  From the education 
perspective, triazine chemistry was adapted for the development of a new organic 
undergraduate laboratory experiment.  The students synthesized a widely used and 
environmentally controversial herbicide, simazine.  The experiment is currently being 
performed by over 1000 students each year at Texas A&M University.  In addition to 
reinforcing nucleophilic aromatic substitution chemistry, this laboratory was intended to 
encourage discussion about the impact that simple chemistry has on society and the 
environment. 
The potential for environmental remediation was realized by the development of 
materials to sequester pollutants such as atrazine.  The modification of chitosan for 
herbicide sequestration was accomplished using triazine chemistry.  Dendrons of 
generation one through three were synthesized on chitosan.  Piperazine groups installed 
during the synthesis effectively sequester atrazine from an aqueous 100 ppb solution, 
presumably irreversibly through covalent bond formation mediated by nucleophilic 
aromatic substitution.  Surprisingly, the first generation graft is as effective as 
subsequent generations at sequestering atrazine.  More than 99% of the atrazine is 
removed from an aqueous solution during a 24 hour period.  The coupling of efficient 
herbicide sequestration to chitosan’s well documented ability for removal of metal 
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contaminants from wastewater and its ability to be woven into fibers, presents many 
possible formulation for this chemistry. 
Dendrimers have found many potential applications in the biomedical field, 
particularly as drug delivery vehicles and imaging agents.  The development of 
macromolecular contrast agents is of great interest to counteract the drawbacks 
associated with currently used, small molecule contrast media.  The use of 
macromolecular contrast agents may reduce the osmotic potential, thereby reducing the 
toxicity of the medium, by increasing the number of iodine atoms on a single molecule.  
Macromolecules may also reduce the dosage necessary as the drug circulates longer, and 
could aid in the detection of cancerous tissue due to preferential accumulation in tumor 
cells.  Triazine dendrimers were synthesized as potential imaging agents.  The synthesis 
proceeded through a divergent pathway utilizing dichlorotriazine building blocks and 
commercially available 2,4-diiodoaniline.  The dendrimers were synthesized in good 
yield with excellent purity using this method.  For triazine-based dendrimers which 
utilize the differential reactivity of cyanuric chloride, any number of targets may be 
envisioned and some are synthetically tractable.  The judicious choice of amine linkers 
and development of more facile synthetic routes ease the synthetic burden.   
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Atrazine, 1H NMR 
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Atrazine, 13C NMR 
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Simazine, 1H NMR 
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Simazine, 13C NMR 
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Preparation of a Triazine Herbicide 
 
Introduction 
 
 The triazine herbicides are the most commonly used herbicides to control 
weeds during the production of corn, sorghum, and sugarcane in the U.S.  More 
than 100,000,000 lbs of these herbicides are used every year in the United 
States.  These herbicides all have a similar structure.  The most common 
triazine herbicides are shown below. 
 
N
N
N
Cl
NHHN
N
N
N
Cl
NHHN
N
N
N
Cl
NHHN
CN
N
N
N
Cl
NHHN
Simazine Atrazine Cyanazine Terbutazine
A triazine ring is an 
aromatic ring with 3 
nitrogen atoms.
 
 
These herbicides work by disrupting photosynthesis in broadleaf weeds.  
Without an ability to do photosynthesis, the weeds die, and crop production 
increases.  Unfortunately, these herbicides are commonly detected in ground 
and drinking water.  These molecules have been banned in Europe because 
their use has been linked to cancer and endocrine gland disruption in people.1, 2 
The EPA has considered restricting or banning their use in this country, but 
longterm costs would range between $295-$665 million a year.2  
   
 The triazine herbicides are prepared by nucleophilic aromatic substitution.  
Let’s break this down: 
 
nucleophile:  a molecule that donates electrons to form a bond 
aromatic:  a ring of 6 atoms with alternating double and single 
bonds (like benzene) 
substitution:  the replacement of one atom for another 
 
 In most nucleophilic aromatic substitution reactions, atoms with lone pairs 
of electrons like nitrogen or oxygen replace halogens like Br, Cl, F, or I.  Here 
are some examples of nucleophilic aromatic substitution reactions. 
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Cl
NO2
OH
NO2
+  NaOH +  NaCl
N Br N OH
+  H2O +  HBr
 
 
These reactions are very similar to the nucleophilic substitution of acid 
chlorides.  When the nucleophile is added to the molecule, the chloride ion is 
released to form the substitution product.  
 
O Cl
+   NH3
N Cl
+   NH3
O NH2
+   HCl
N NH2
+   HCl
 
 
  
In this laboratory experiment, we will synthesize simazine.  This reaction 
sequence involves the substitution of two chlorine atoms of cyanuric chloride 
with two ethylamine groups as shown below. 
 
N
N
N
Cl
ClCl
NH2
NH
N
N
N
Cl
HN NH3
+  Cl-
acetone
0 oC - 25 oC
+  4
Cyanuric
Chloride
SimazineEthylamine
+  2
 
 
Since HCl is produced as a by-product of this reaction, excess base 
(ethylamine) is necessary to neutralize the acid (HCl) produced.  The 
substitution of cyanuric chloride is temperature dependent.  By controlling the 
amount of nucleophile added and the reaction temperature, one, two, or even all 
three chlorides of cyanuric chloride can undergo substitution, as shown below.   
N
N
N
Cl
ClCl acetone, 0
 oC
NH2
NH
N
N
N
Cl
Cl
2
acetone, 25 oC
NH2
NH
N
N
N
Cl
HN
2
acetone, 70 oC
NH2
NH
N
N
N
NH
HN
2
 
 
 
 112
Objectives 
 
 1.  To complete a laboratory synthesis of the herbicide simazine using 
nucleophilic aromatic substitution. 
 2.  To use previously acquired laboratory techniques to characterize the 
product obtained. 
 
Procedure 
 
Preparation of Simazine 
 1. Prepare an ice bath using a 400 mL plastic beaker and place the bath on 
magnetic stir plate. 
 2. In a 100-mL round-bottomed flask, place a stir bar and add 5 mL of the 
0.5 M cyanuric chloride solution using the autodispenser in the hood.  
Cover the flask with foil to prevent evaporation of the solvent. 
 3. Clamp the flask in the ice bath, and allow the solution to sit and cool in 
the ice bath for about 10 min. while stirring with the magnetic stirrer. 
 4. From the volume of cyanuric chloride solution obtained and its 
concentration, calculate the theoretical yield of simazine.  Record this 
value.  
 5. Obtain 10 mL of ethylamine solution (1.0 M in acetone/water) in a 
graduated cylinder from the autodispenser in the hood.  Using a long stem funnel, 
carefully add the ethylamine while the solution is stirring.  After 5 min., remove the 
ice bath and continue to stir the reaction for an additional 30 min. as it comes to 
room temperature. 
 
CAUTION:  Always wear appropriate eye protection.  Cyanuric 
chloride will irritate your nose and eyes.  Ethylamine will irritate 
your nose, eyes, and skin. Handle these chemicals with care and 
dispense in the hood. 
 
 6. Adding water will precipitate the simazine out of solution.  Add about 30 
mL of distilled water to the flask and stir for 5 min.  
 7. Collect your sample by filtering using a Büchner funnel and a 250-mL 
filter flask connected to a water aspirator for suction.  Be sure to wet the 
filter paper with distilled water before adding your sample.  Carefully pour 
the contents of your reaction flask into the funnel.  Rinse the flask well 
with at least two 30 mL portions of distilled water and one 30 mL portion 
of methanol filtering each through the funnel to wash the product. 
 8. Continue suction through your sample for several minutes in order to dry 
it.  Disconnect the rubber tubing from the filter before turning off the 
water. 
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 9. Using a spatula, remove the sample from the filter paper and place it in a 
piece of folded filter paper and press until it is dry. 
     10. Weigh a watch glass.  Add your dried sample and reweigh.  Calculate the 
weight of simazine obtained.  Determine the percent yield.  Record these 
values. 
 
Characterization of Simazine 
 
1. Melting Point  
 a) Obtain two melting point capillary tubes.   
 b) Place a small amount of your compound onto a clean watch glass.  Load 
your compound into the capillary tubes by pressing the open end of the 
tube into the solid, inverting the tube, and gently tapping the closed end 
on the bench top until the solid moves to the bottom. 
 c) Once you have obtained about 2 to 3 mm of sample in the bottom of the 
tubes, place the melting point capillary with your sample into the Mel-
Temp apparatus with the open end up.  Begin heating at a rate of 10 
°C/min.  Carefully observe the solid within the melting point capillary and 
record the temperature at the first sign of melting (when the solid starts to 
turn to a liquid).  Also record the temperature when the entire solid has 
melted (when it is completely liquid). 
 d) Turn off the Mel-Temp and allow the temperature to cool to about 15 °C 
below the point at which you first observed melting.  (This may be done 
quickly by passing compressed air over the apparatus.) 
 e) Using the second melting point capillary tube containing your compound 
you prepared, determine the melting point by allowing the sample to heat 
at a rate of 1 to 2 °C/min.  Record the melting point range obtained. 
  
 
2.  Thin Layer Chromatography    
 a)   Put approximately 6 mL of the TLC developing solvent (mixture of 75% 
hexanes and 25% ethyl acetate) into the TLC jar.  Replace the lid and 
shake gently to saturate the air in the jar with the vapor of the solvent. 
 b) Draw a light line with a pencil 1/2-inch from the bottom of the TLC plate.  
Be sure the line will be above the solvent level in the TLC jar. 
 c) Dissolve a small quantity of your sample (about the size of a pea) in 
about 8 mL of acetone found in the fume hood.  Use a TLC spotting 
capillary tube to apply a small dot of the solution on the line and allow the 
spot to dry. 
 d) Put the TLC plate in the TLC jar, quickly replace the lid, and leave the jar 
undisturbed while the plate develops.  Allow the solvent to ascend the 
plate until it is about 1/2-inch from the top of the plate.  Remove the plate 
and quickly mark the top of the solvent line with a pencil. 
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 e) After the solvent has evaporated, observe the TLC plate under a UV 
lamp.  Lightly draw a circle with a pencil around any spot(s) you can see 
under the UV lamp. 
f) Determine the Rf value of the spot(s) observed, and record the value(s). 
 
Clean-up Procedures:   
Dispose of solid crystals, filter paper, and TLC plates in solid waste 
container provided.  Dispose of liquid waste in appropriately 
labeled liquid waste bottle. 
 
1 Baumann, P.A.; Ketchersid, M. Texas Agricultural Extension Service Report L-5204; Texas 
A&M University:  College Station, TX, Oct 1999. 
 
2 Ribaudo, M.O.; Bouzaher, A.  Agricultural Economic Report No. 699; Resources and 
Technology Division, Economic Research Service, U.S. Department of Agriculture:  Washington, 
D.C., 1994. 
 
This Lab Experiment was developed by Dr. Eric Simanek and Susan Hatfield, 
Texas A&M University 
 
 
Pre-lab Questions         
 
1. Calculate the molecular weights of cyanuric chloride and simazine. 
 
2. Predict the products of the following nucleophilic aromatic substitution 
reactions. 
 
 a)     b)    c)  
 
 
 
 
 
 
In-lab Observations  
              
1.  Volume of cyanuric chloride:    ___________mL 
 
2.  Concentration of cyanuric chloride:   ___________M  (mol/L) 
 
3.  Moles of cyanuric chloride:    ___________mols 
 
4.  Theoretical Yield:     ___________g  Simazine 
Br
NO2
NO2
+ NH3 N
N
N
Cl
ClCl
6 H2O+
Cl
NO2
NO2
NaOH+
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5.  Volume of ethylamine:     ___________mL 
 
6.  Weight of watch glass:     ___________g 
7.  Weight of simazine sample and watch glass: ___________g 
 
8.  Weight of simazine sample:    ___________g 
 
9.  Percent Yield:      ___________% 
 
10.  Melting Point determination #1:   ___________°C 
 
       Melting Point determination #2:   ___________°C 
 
11.  Rf  value(s)      ___________ 
 
Post-lab Questions      
 
1.  Draw the side product that could be formed during the synthesis of simazine 
if:   a) Not enough amine was added 
 
 b) Too much amine was added and the solution was heated 
 
 c) Sodium Hydroxide was present (Several different products are possible 
here.  Just draw one.) 
 
2.  The melting point of pure simazine is 225 - 227 °C.  If the melting point of 
your product is different, why? 
 
3.  What are possible causes for obtaining a low percent yield in this reaction? 
 
4.  What are the possible causes of obtaining a percent yield greater than 
100%? 
 
5. What happens to the HCl produced during the synthesis of simazine? 
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IR−Chitosan:  Low MW, Med. MW, and High MW 
 
 
118
IR−NaOH-treated Chitosan:  Low MW, Med. MW, and High MW 
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IR−Chitosan G1-Cl:  Low MW, Med. MW, and High MW 
 
 
 
120
IR−Chitosan G1-NH:  Low MW, Med. MW, and High MW 
 
 
121
IR−Chitosan G2-Cl:  Low MW, Med. MW, and High MW 
 
 
122
IR−Chitosan G2-NH:  Low MW, Med. MW, and High MW 
 
 
123
IR−Chitosan G3-Cl:  Low MW, Med. MW, and High MW 
 
124
IR−Chitosan G3-NH:  Low MW, Med. MW, and High MW 
 
125
IR−Low MW Chitosan:  Unmodified, G1-Cl, G1-NH 
 
126
IR−Med MW Chitosan:  Unmodified, G1-Cl, G1-NH  
 
127
IR−High MW Chitosan:  Unmodified, G1-Cl, G1-NH 
 
128
IR−Low MW Chitosan:  Unmodified, G1-Cl, G1-NH, G2-Cl, G2-NH, G3-Cl, G3-NH  
 
129
TGA Low MW Chitosan:  Unmodified, G1-Cl, G1-NH 
 
 
130
TGA Low MW Chitosan Derivative:  Unmodified, G1-Cl, G1-NH 
 
131
TGA Low MW Chitosan:  Unmodified, G1-NH, G2-NH, G3-NH 
 
132
TGA Low MW Chitosan Derivative:  Unmodified, G1-NH, G2-NH, G3-NH 
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Isosteric Dendrimer Synthesis:  Compound 1, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 1, 13C NMR 
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Isosteric Dendrimer Synthesis:  Intermediate 1, ESI-MS  
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Isosteric Dendrimer Synthesis:  Compound 2, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 2, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 2, ESI-MS 
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Isosteric Dendrimer Synthesis:  Compound 3, 1H NMR 
 
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 -3
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
Chloroform-d
N
H
NHBocBocHN
 
141
Isosteric Dendrimer Synthesis:  Compound 3, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 3, ESI-MS 
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Isosteric Dendrimer Synthesis:  Compound 4, 1H NMR 
 
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 -3
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
Chloroform-d
N
N
N
N
NHBocBocHN
N
BocHN
NHBoc
Cl
 
144
Isosteric Dendrimer Synthesis:  Compound 4, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 4, ESI-MS 
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Isosteric Dendrimer Synthesis:  Compound 5-N, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 5-N, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 5-N, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 5-O, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 5-O, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 5-O, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 5-C, 1H NMR  
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Isosteric Dendrimer Synthesis:  Compound 5-C, 13C NMR  
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Isosteric Dendrimer Synthesis:  Compound 5-C, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 6-N, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 6-N, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 6-N, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 6-O, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 6-O, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 6-O, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 6-C, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 6-C, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 6-C, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 7-N, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 7-N, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 7-N, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 7-O, 1H NMR 
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Isosteric Dendrimer Synthesis:  Compound 7-O, 13C NMR 
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Isosteric Dendrimer Synthesis:  Compound 7-O, MALDI-MS 
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Isosteric Dendrimer Synthesis:  Compound 7-C, 1H NMR  
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Isosteric Dendrimer Synthesis:  Compound 7-C, 13C NMR  
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Isosteric Dendrimer Synthesis:  Compound 7-C, MALDI-MS  
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pH Responsive Dendrimer:  Compound 8, 1H NMR 
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pH Responsive Dendrimer:  Compound 8, 13C NMR 
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pH Responsive Dendrimer:  Compound 8, APCI-MS 
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pH Responsive Dendrimer:  Compound 9, 1H NMR 
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pH Responsive Dendrimer:  Compound 9, 13C NMR 
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pH Responsive Dendrimer:  Compound 9, ESI-MS 
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pH Responsive Dendrimer:  Compound 10, 1H NMR 
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pH Responsive Dendrimer:  Compound 10, 13C NMR 
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pH Responsive Dendrimer:  Compound 10 ESI-MS 
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pH Responsive Dendrimer:  Compound 11, 1H NMR 
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pH Responsive Dendrimer:  Compound 11, 13C NMR 
 
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
 
184
pH Responsive Dendrimer:  Compound 11, MALDI-MS 
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pH Responsive Dendrimer:  Compound 12, 1H NMR 
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pH Responsive Dendrimer:  Compound 12, 13C NMR 
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pH Responsive Dendrimer:  Compound 12, ESI-MS 
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pH Responsive Dendrimer:  Compound 13, 1H NMR 
 
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 -3
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
N
NN
N
H
N
H
NH
N
BocN
N
N
BocN
NBoc
 
189
pH Responsive Dendrimer:  Compound 13, 13C NMR 
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pH Responsive Dendrimer:  Compound 13, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 15, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 15, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 15, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 16, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 16, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 16, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 17, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 17, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 17, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 18, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 18, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 18, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 19, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 19, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 19, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 20, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 20, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 20, ESI-MS 
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Divergent Diversity Dendrimer:  Compound 21, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 21, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 21, MALDI-MS 
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Divergent Diversity Dendrimer:  Compound 22, 1H NMR 
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Divergent Diversity Dendrimer:  Compound 22, 13C NMR 
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Divergent Diversity Dendrimer:  Compound 22, MALDI-MS 
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Divergent Diversity Dendrimer:  Compound 23, MALDI-MS 
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Divergent Diversity Dendrimer:  Compound 24, MALDI-MS 
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Iodinated Dendrimer:  Compound 25, 1H NMR 
 
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 -3
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
N
N
N
N
R R
N
N
N
N
Cl N
NHBoc
NHBoc
R=
 
218
Iodinated Dendrimer:  Compound 25, 13C NMR 
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Iodinated Dendrimer:  Compound 25, MALDI-MS 
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Iodinated Dendrimer:  Compound 26, 1H NMR 
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Iodinated Dendrimer:  Compound 26, 13C NMR 
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Iodinated Dendrimer:  Compound 26, MALDI-MS 
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Iodinated Dendrimer:  Compound 27, 1H NMR 
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Iodinated Dendrimer:  Compound 27, 13C NMR 
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Iodinated Dendrimer:  Compound 27, MALDI-MS 
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Iodinated Dendrimer:  Compound 28, 1H NMR 
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Iodinated Dendrimer:  Compound 28, 13C NMR 
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Iodinated Dendrimer:  Compound 28, MALDI-MS 
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Iodinated Dendrimer:  Compound 29, 1H NMR 
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Iodinated Dendrimer:  Compound 29, 13C NMR 
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Iodinated Dendrimer:  Compound 29, MALDI-MS 
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Iodinated Dendrimer:  Compound 30, 1H NMR 
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Iodinated Dendrimer:  Compound 30, 13C NMR 
 
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
 
234
Iodinated Dendrimer:  Compound 30, MALDI-MS 
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Iodinated Dendrimer:  Compound 31, 1H NMR 
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Iodinated Dendrimer:  Compound 31, 13C NMR 
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 Iodinated Dendrimer:  Compound 32, 1H NMR 
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Iodinated Dendrimer:  Compound 32, 13C NMR 
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Iodinated Dendrimer:  Compound 32, MALDI-MS 
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Iodinated Dendrimer:  Compound 33, 1H NMR 
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Iodinated Dendrimer:  Compound 33, 13C NMR 
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Iodinated Dendrimer:  Compound 33, MALDI-MS 
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Iodinated Dendrimer:  Compound 34, 1H NMR 
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Iodinated Dendrimer:  Compound 34, 13C NMR 
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Iodinated Dendrimer:  Compound 34, MALDI-MS 
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Iodinated Dendrimer:  Compound 34, Elemental Analysis 
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Iodinated Dendrimer:  Compound 34, GPC Data 
 
 
248
Iodinated Dendrimer:  Compound 35, 1H NMR 
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Iodinated Dendrimer:  Compound 35, 13C NMR 
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Iodinated Dendrimer:  Compound 35, MALDI-MS 
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Iodinated Dendrimer:  Compound 35, HPLC 
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 Name Retention Time Area % Area Height Int Type 
1 SH4-83 10.292 118449 100.00 2771 BB 
2 NaNO3 13.447
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Iodinated Dendrimer:  Compound 36, 1H NMR 
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 Iodinated Dendrimer:  Compound 36, MALDI-MS 
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Iodinated Dendrimer:  Compound 36, HPLC 
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 Name Retention Time Area % Area Height Int Type 
1 SH4-67 10.293 525739 100.00 15544 BB 
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Iodinated Dendrimer:  Compound 36, GPC data 
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